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Abstract
Studies o f the mechanisms underlying memory formation have defined central 
roles for CRE-dependent gene expression, which is mediated by the transcription 
factor CREB and the coactivator CBP. CBP creates a bridge between CREB and 
the basal transcriptional machinery and acetylates histones, which induces 
chromosomal changes and results in loss of chromosomal repression. This allows 
successful transcription o f the underlying genes needed for synthesis of proteins 
underlying memory formation. CBP has been linked to neurodegenerative 
diseases and cerebral CBP levels were shown to reduce in mice lacking functional 
presenilins (PSs), a class o f enzymes that has been associated with Alzheimer’s 
Disease (AD).
In this thesis it is shown that WT PS1 stimulates the transcriptional activating 
ability o f CBP and its close homolog p300, whereas an Alzheimer’s disease- 
associated N terminal mutant of PS 1 did not produce this effect. Interestingly, PS 1 
C terminal mutants produced a reduction in CBP transcriptional activating ability, 
compared to control levels.
Additionally, we showed that wild type PS1 increases the endogenous CBP level. 
Moreover, an increase in CBP endogenous levels was noted when the cells were 
transfected with the -M146L N-terminal mutant o f PSI. However, these levels 
were still significantly lower when compared to cells transfected with wild type 
PSI. We were also able to show that knockdown o f endogenous PSI leads to a 
decrease in endogenous CBP levels and a decrease in CBP activity. Hence, PSI 
can affect both the level and the activity of CBP.
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In addition, the activation of CBP by WT PSI involves the PI 3-kinase, p38 MAP 
kinase and p42/p44 MAP kinase pathways and targets primarily the C terminus o f 
CBP. It is also shown that the effect o f wild-type PSI is dependent on the histone 
acetyltransferase activity (HAT) of CBP. Moreover, it was demonstrated that WT 
PSI, but not its M146L mutant, could increase the promoter activity of c-fos, a 
CBP HAT dependent target gene.
A dditionally, we showed that application of the histone deacetylase inhibitor, 
TSA, rescued the long-term potentiation and long-term memory defects shown by 
APP/PS1 mutant mice. Moreover, it was shown that the acetylation level of 
histone H4 in APP/PS1 mice is lower than that o f WT littermates and that TSA 
injection restores the acetylation of these histones. This is the first study to 
identify AD as a disease of epigenetic etiology and suggests that enhancing 
histone acetylation may have potential for the treatment o f AD.
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Chapter 1
1 INTRODUCTION
Cognition can be defined as the acquisition, storing and processing of information 
in order to be retrieved by the brain. Thus, it is not surprising that cognition relies 
on our ability to form and retrieve long lasting memories, which allows us to 
recognize our friends, obtain a language, learn and think. In essence, memory is 
what allows us to define who we are through personal memories and experiences, 
which distinguishes us from one another.
The nobel laureate Eric Kandel described the process o f memory storage as a 
dialogue between genes and synapses(Kandel, 2001). Kandel and other 
researchers were able to show that the formation o f long-term memory (LTM) is 
dependent upon DNA converstion into RNA (transcription)(Dash et al., 1990), 
synthesis o f new protein(Montarolo et al., 1986) and structural change o f the 
synapse(Bailey and Chen, 1983). In addition, work from several laboratories 
showed that the proper regulation o f gene expression in LTM is not only 
controlled by the transcriptional machinery but also modulated by epigenetics. 
Epigenetics is defined as the mechanism that changes gene expression by 
'marking' DNA or its associated proteins, through processes such as DNA 
methylation and histone modification, without changing the DNA sequence 
itself(Rakyan et al., 2001). Epigenetic mechanisms are increasingly recognized for 
their contribution to the tight regulation of gene activation and silencing. Hence, it 
is not surprising that deregulation of one o f the epigenetic mechanisms and the 
transcription machinery might lead to disruption of memory associated gene 
expression, resulting in a number of syndromes associated with mental disorders.
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In the next sections I will discuss about chromatin and transcription factors and 
their importance in the gene expression.
1.1 Chromatin modifications and the regulation of gene expression
The human genome consists of over three billion base pairs (bp), which If 
stretched out, would form very thin thread, about 2 meters long(Alberts, 2004). In 
order to fit the long strands of DNA into the nucleus, which is only 10 pm in 
diameter, nature requires a sophisticated way to pack the DNA without 
compromising its accessibility (Fig 1.1). DNA is wrapped around an octamer 
complex o f histones to form nucleosomal units, giving the appearance of beads on 
a string (Lander et al., 2001). The histones are small proteins with a positive 
charge, which enable them to interact with the negative backbone o f DNA. Each 
nucleosomal unit consists of about 200 bp of DNA, of which 147 bp are wrapped 
around the histone octamer complex and the remaining base pairs form a linker to 
the next nucleosome (linker DNA). Each histone octamer complex contains two 
copies o f histones H3 and H4 bordered by two copies of histones H2A and 
H2B(Komberg and Lorch, 1999).
Each histone has a long N-terminal ‘tail’ extension that protrudes from the 
nucleosome core (Fig 1.2). These tails are the main target for histone modification 
and serves as a binding site for gene activators and repressors. The histone tails 
are also thought to create a higher level of chromatin folding by interacting with 
other nucleosomes(Dorigo et al., 2004; Komberg and Lorch, 1999). The 
nucleosome structure is further compacted into a solenoid structure in genes that 
are not transcriptionally active or about to become transcriptionally active. On the
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other hand, active or potentially active genes are found in an open nucleosomal 
structure.
Figure 1.1 Organization of DNA in the eukaryotic nucleus
The figure was obtained from www.Epitron.eu
Complete Histone With 
DNA
H2A-H2B
DimerH3-H4
Dimer
Hisfone bctam er
Tetramer
Figure 1.2 The assembly of the core histones into the nucleosome
Each o f the core histones contains a histone-fold domain that allow heterodimeric 
interactions between core histones. The H3-H4 tetramer forms the scaffold o f  the 
octamer onto which two H2A-H2B dimers are added to complete the assembly.
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Chromatin can be found in two different states; euchromatin and heterochromatin. 
Euchromatin is generally regarded as an open chromatin structure associated with 
active genes, whereas heterochromatin is considered to be tightly packed 
chromatin with transcriptionally silent DNA. The random inactivation o f one of 
two X chromosomes in the cells of female embiyos is an example of chromatin 
inactivation forming a heterochromatic structure called the Barr body(Avner and 
Heard, 2001). Tightly packed DNA creates a barrier for the molecular 
transcriptional machinery that needs access to the information encoded by the 
DNA.
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1.2 Biochemistry of chromatin
Biochemical activities that modify chromatin structure are usually divided into 
three groups (i) chromatin remodelling catalyzed by specific large protein 
complexes containing specific enzymes that hydrolyze ATP (ii) covalent 
posttranslational modification o f histone tails (iii) histone variants with 
specialized properties.
Since one of the main topics of this thesis is histone post-translational 
modification, the role of chromatin remodelling by ATP hydrolysis protein or the 
role of histone variants will not be discussed in this thesis (For review (Li et al., 
2007).
1.2.1 Histone modifications
The histone cores and in particular their tails, are targets for a considerable 
number o f covalent modifications, such as acetylation, ubiquitination, 
phosphorylation and methylation(Biel et al., 2005). Conventionally, some histone 
modifications are associated with active gene activation, such as H3 Lys4 
methylation and H3 Lys56 acetylation. On the other hand, other histone 
modifications associated with the inactivation of gene transcription have been 
identified, such as H3 Lys27 methylation and H2A L y sll9  ubiquitination. 
Histone modifications both individually and in combination have been proposed 
to be involved in gene regulation by modifying the chromatin accessibility and by
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acting as docking sites for transcription factors (see section XXX)(de la Cruz et 
al., 2005; Strahl and Allis, 2000). Interestingly, different histone modifications 
can interact with one another. For example, H3 Lys9 demethylation facilitates H3 
Ser 10 phosphorylation and Lysl4 acetylation. Post-translational modifications in 
nucleosomal histones and their combinations seem to be related with, and even 
predict, transcriptional states. This led to the idea of a histone code whereby 
“distinct histone amino-terminal modifications can generate synergistic or 
antagonistic interaction affinities for chromatin-associated proteins”(Jenuwein and 
Allis, 2001). As this thesis is mainly concerned with histone acetylation, other 
modifications will be discussed only briefly.
(a) Histone methylation 
Histone methylation, was first described in 1964(Murray, 1964), and histone 
methyltransferase enzymes (HMT) were found to act on the lysine or arginine 
residues of the histone tail(Peterson and Laniel, 2004). For a long time 
methylated histone was thought to be highly stable and only recently a histone 
demethylase was discovered(Shi et al., 2004). The methylation of histones plays 
an important role in chromatin regulation and is linked to both gene expression 
and silencing(Zhang and Reinberg, 2001). Methylation o f histone H3 on Lys9 is 
associated with heterochromatin formation and gene repression(Nakayama et al., 
2001). In contrast, methylation o f H3-K4 is linked to gene activation(Santos-Rosa 
et al., 2002).
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(b) Histone phosphorylation
Phosphorylation can occur at serines and threonines of all the histone tails. 
Histone phosphorylation was found to be involved in DNA repair, apoptosis and 
mitotic chromosome condensation(Peterson and Laniel, 2004). Phosphorylation of 
H3 on its Ser 10 is involved in gene activation by promoting H3 Lysl4 
acetylation(Agalioti et al., 2002). Moreover, initial studies showed that histone 
phosphorylation has a role in transcriptional induction o f immediate early genes in 
mammalian cells, such as the c-Fos gene(Mahadevan et al., 1991). Finally, heat- 
shock gene induction in Drosophila is accompanied by dramatic increases in 
histone H3 Ser-10 phosphorylation that occurs at transcriptionally active 
loci(Nowak and Corces, 2000).
(c) Histone acetylation
One of the most studied histone modifications is the acetylation of the 
evolutionary conserved lysine residues on the histone N-termini by histone 
acetyltransferases (HAT). Lysine acetylation was found to change the net charge 
of nucleosomes, resulting in the relaxation of DNA-histone interactions, altering 
the chromatin structure that enables gene transcription. Moreover, histone 
acetylation was shown to enhance binding o f several gene activation factors, 
which contain a region known as the bromodomain. Thus, the bromodomain binds 
with greater affinity to histones when specific lysines are acetylated. In contrast, 
histone deacetylation, catalyzed by histone deacetylases (HDAC), was found to 
package the DNA into a more condensed form, limiting the access o f transcription 
factors and thus acting as a gene silencer(Ng and Bird, 2000). Both HATs and 
HDACs (Fig 1.3) generally lack intrinsic DNA-binding activity. Instead, they are
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recruited to DNA by sequence-specific transcription factors to stimulate either 
transcriptional activation or repression (see section 1.4). Interestingly, Levenson 
et al. (2004) were able to show that increased acetylation of histone 3 in area CA1 
of the hippocampus occurs following contextual fear conditioning, a form of 
associative memory in which mice associate a novel context with an aversive 
stimulus. Additionally, by inhibiting HDAC, they were able to manipulate 
changes in the chromatin that might enhance transcription of genes associated 
with the formation of LTM(Levenson et al., 2004).
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Figure 1.3 Histone acetylation and deacetylation
Transcriptional activators and repressors are associated with co-activators and co- 
repressors, which have HAT and HDAC activities, respectively. Histone 
acetylation is characteristic o f actively transcribed chromatin and may weaken the 
binding o f  histones to DNA or alter their interactions with other proteins 
(modified from (Cooper, 2000)).
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1.3 HATs and HDACs
1.3.1 HDACs
Mammalian HDACs can be divided into the classical and the silent information 
regulator 2 (Sir2)- related protein (sirtruin) families(Yang and Seto, 2007). In 
humans, members of the classical family have another subdivision, which include 
class I, II and IV, that share sequence similarity and require Zn+ for deacetylase 
activity. Class I HDACs (HDAC 1-3, HDAC8) are related to the yeast gene 
repressor Rpd3p, and are subunits of at least two distinct co-repressor complexes, 
the Sin3 complex and the NuRD complex. Class II HDACs (HDAC4-7, 9 and 10) 
are similar to the yeast Hdalp HDAC, they act as gene repressors and have been 
implicated in various roles in cell differentiation and development. Class IV 
comprises HDAC 11, which has some features o f both class I and II HDACs. The 
sirtruin family includes class III HDACs (SIRT1-7), which are similar to yeast 
Sir2. Class III HDACs are biochemically and structurally distinct from the 
classical family and require NAD+ as a cofactor. HDACs appear to be involved in 
gene silencing and heterochromatin formation at centromeres and telomeres (for 
review (Gregoretti et al., 2004)).
1.3.2 HATs
HATs were found to be involved in histone acetylation (leading to gene 
activation), chromosome decondensation, DNA repair and non-histone substrate 
modification. All HATs share a highly conserved motif containing an acetyl-CoA 
binding site (Roth et al. 2001) and can be subdivided into several classes based on 
their sequence homologies. Historically, HATs have been divided into type A
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(nuclear), and type B (cytoplasmic) HATs. However, this distinction between B 
and A type o f HATs is somewhat unclear, since HATs can shuttle between 
nucleus and cytoplasm. More accurately, HAT complexes can be classified into 
several subfamilies based on their sequence homologies (Table 1.1).
The general control non-derepressible 5 (Gcn5) is the founding member of the 
Gcn5 N-acetyltransferases (GNATs). The GNAT family members include Gcn5, 
PCAF, Elp3, HATlm Hpa2 and Nutl. The MYST family is named after the 
founding members of the family: Morf, Ybf2, Sas2 and Tip60(Kimura et al., 
2005).In addition, other proteins including CBP/p300, Tafl and a number of 
nuclear receptor co-activators have been shown to possess intrinsic HAT activity. 
However, these proteins do not contain a consensus domain and therefore 
represent an ‘orphan class’ o f HAT enzymes(Kimura et al., 2005).
One characteristic of many, if not all, HATs is that they do not work in isolation 
in vivo. Interestingly, some HATs appear to associate with other HATs and co­
activators for regulation o f specific target genes. It was recognized that 
recombinant forms of several HATs, notably Gcn5, fail to acetylate nucleosomal 
substrates efficiently relative to mixes o f free histone. Results with several HATs 
suggest that tail accessibility is a major factor affecting the rate of acetylation in 
oligonucleosome arrays(Herrera et al., 2000; Verreault et al., 1998), 
demonstrating that native HAT complexes, working alone or together with yet 
other chromatin remodeling complexes, such as SWI/SNF(Krebs et al., 2000), 
must in some way overcome the difficulty o f tail accessibility in unmodified 
chromatin. To date, the best-characterized HAT complexes are those that contain
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yeast Gcn5, such as SAGA and ADA(Grant et al., 1997; Sendra et al., 2000). 
Moreover, some HAT subunits were shown to have domains that cooperate to 
recruit the HAT to the appropriate location on the genome. These domains include 
bromodomains, chromodomains, WD40 repeats, Tudor domains and PHD fingers 
that bind to chromatin and recognise histone tails(Lee and Workman, 2007).
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Group HAT Organism Possible function R ef
GNATs family Gen5 yeast transcriptional activation (Brownell et al., 1996)
Gen5L mammal/fly transcriptional activation (Smith et al., 1998a; Xu et al., 1998)
PCAF mammal transcriptional activation (Yang et al., 1996)
M YST family Tip60 mammal transcriptional activation/D NA  repair (Y am am oto and Horikoshi, 1997)
HB01 mammal gene expression?/DNA replication? (Iizuka and Stillman, 1999)
M ORF mammal transcriptional activation (Champagne et al., 1999)
MOZ mammal transcriptional activation (Cham pagne et al., 2001)
MOF mam mal/fly transcriptional activation (H ilfikere t al., 1997)
Esal yeast transcriptional activation (Smith et al., 1998b)
Sas3 yeast transcriptional activation? (Takechi and Nakayama, 1999)
Sas2 yeast anti-silencing (K im ura et al., 2002; Sutton et al., 2003)
'Orphan' class HAT1 yeast histone deposition (K le ffe t al., 1995)
p3 00/C BP mammal transcriptional activation (Ogryzko et al., 1996)
TAF|]250 (TAF1) m am m al/fly/yeast RNA pol II transcription (M izzen et al., 1996)
ACTR/SRC-1 mammal transcriptional activation (Chen et al., 1997; Spencer et al., 1997)
Elp3 yeast transcriptional elongation (W ittschieben e ta l., 1999)
hT FIIIC l 10 mammal RNA pol II transcription (Kundu et al., 1999)
hTF!IC90 mammal RNA pol II transcription (Hsieh et al., 1999)2
Hpa2 yeast ? (Angus-Hill et al., 1999)
N utl yeast RNA pol II transcription (Lorch et al., 2000)
ATF-2 mammal transcriptional activation (Kawasaki et al., 2000)
Table 1.1 A list of identified histone acetyltransferase.
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1.4 Transcription
The tightly regulated expression of the thousands of genes of the eukaryotic 
genome is crucial for the proper development and the normal functioning of all 
organisms. Once the chromatin has been opened it then needs to be transcribed. 
Different genes are transcribed in different cell types leading to the production of 
their corresponding proteins. In addition, different stimuli will trigger new protein 
synthesis by activating transcription of specific genes. Control over gene 
expression is achieved by regulation of transcription, the process by which DNA 
is copied into RNA transcript. In a eukaryotic cell, the transcription process 
requires three members o f the RNA polymerase family. RNA polymerase I and 
III, which transcribe respectively rRNA or tRNA and other small RNAs, and 
RNA polymerase II, which transcribes the vast majority of protein coding genes. 
Although prokaryotic RNA polymerase can initiate transcription on its own, 
eukaryotic polymerases require the prior assembly of transcription factors at short 
defined segments of double-helical DNA (gene promoter).
Transcription factors, which utilize RNA polymerase II, are divided into two main 
groups(Villard, 2004):
1. Basal transcription factors, which recruit the RNA polymerase II 
multi-protein complex to a promoter, which often contains a conserved 
DNA sequence motif called the TATA box (Fig 1.4).
2. Gene-specific transcription factors, which bind to a specific DNA 
sequence and regulate the basal transcription complex either by 
activating or repressing it.
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Generally, regulatory transcription factors bind to gene promoters and activate or 
inhibit transcription. Numerous transcription factors have been identified in a 
wide variety o f organisms. Many of these transcription factors are activators and 
have several modules in common: (1) A DNA-binding domain that positions the 
protein on specific sequences. (2) Activation domains that are thought to work by 
recruiting or accelerating the assembly of the general transcription factors on the 
promoters. Transcription factors that do not bind to the DNA directly but link a 
DNA-binding transcriptional activator to the basal transcription complex are 
referred to as co-activators. On the other hand, a number o f cases have now been 
demonstrated in which a transcription factor exerts an inhibitory effect, directly or 
indirectly, on transcription initiation(Latchman, 2007). Since this thesis deals 
mainly with transcription activation, transcription repression will not be discussed 
(For review(Latchman, 2007)).
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Figure 1.4 RNA Polymerase II Transcription-initiation Complex
Stepwise assembly o f  a transcription-initiation complex from isolated RNA 
polymerase II and basal transcription factors (figure modified from (Lodish H., 
2000)).
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1.4.1 DNA binding domains
Research into the DNA binding domains of different transcription factors have 
shown that there are several groups with common structural elements that are able 
to bind to specific DNA sites. The ability of transcription factors to bind to DNA 
is of great importance since DNA-binding serves as the first step of the 
transcription process. A DNA binding domain can recognise DNA via a variety of 
specific structural motifs, such as helix-tum-helix motif, zinc finger motif and the 
basic DNA binding domain. The basic DNA-binding domain, which is associated 
with a leucine zipper motif or a helix-loop-helix motif, possesses the unique 
ability to bind DNA as a dimer of two transcription factors. In addition, the basic 
DNA-binding domain is characterised by a large positive charge, which allows the 
binding domain to be structured into an a-helix when interacting with 
DNA(Weiss et al., 1990). The exact amino acid sequence that is folded into the 
DNA-binding motif determines the particular DNA sequence that is 
recognised(Alberts, 2004).
1.4.2 Activation domains
Current evidence indicates that following DNA binding, a transcription factor 
influences gene expression through its trans-activation domain. In most cases the 
activation domain ranges from 30 to 100 amino acids in length and falls into three 
distinct families having respectively; acidic, glutamine-rich and proline-rich 
domains(Latchman, 2007). Activation domains may act directly, or may recruit a 
co-activator that possesses activation properties and the ability to interact with the 
basal transcription complex. It seems that binding o f the basal transcriptional 
complex to the TATA box produces only a low rate of transcription; however, this
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rate can be greatly increased by the binding of other transcription factors to 
upstream sequences. Such interactions seem to enhance transcription by 
increasing the rate of transcription factor complex assembly or by stimulating the 
level o f its activity(Latchman, 2007).
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1.5 The regulation of transcription factors
As mentioned above, transcription factors play a key role in the transcription of 
genes. Regulation of gene expression can be achieved through control of 
transcription factors either by regulating their synthesis or activating their inactive 
form by post-translational modification(Latchman, 2007).
1.5.1 Regulation of transcription factor synthesis
Specific transcription factors are synthesised at certain stages of development and 
in specific cell types, thus resulting in tissue-specific gene expression. One such 
example is the Myod transcription factor. Synthesised by skeletal muscle cells, 
Myod was found to regulate gene expression of for example, creatine kinase. 
Interestingly, it was shown that artificial induction o f Myod expression in other 
cell types, such as fibroblast cells, was sufficient to convert them into skeletal 
muscle cells (Weintraub et al., 1989).
1.5.2 Regulation of transcription factor activity
Synthesis o f transcription factors is an important control point in transcription 
factor regulation, however it is not sufficient. It is also necessary to have a 
mechanism by which pre-existing transcription factors can be transformed from 
an inactive to an active form by posttranslational changes. Such activation can 
take place through several mechanisms, such as ligand binding, protein-protein 
interaction and protein modification (Fig 1.5).
An example o f a transcription factor whose activity is regulated is CREB (cyclic
AMP response element (CRE) binding protein). CREB, which has a basic DNA
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binding domain, was shown to bind to the palindromic CRE sequence, 
TGACGTCA, as a dimer through each CREB monomer binding to one half of the 
CRE sequence. The CREB factor is found in cells in its inactive form prior to its 
activation following cyclic AMP treatment. Moreover, CREB can be found bound 
to CRE before exposure to cyclic AMP but the DNA-bound CREB does not 
activate transcription. An increase in levels o f cyclic AMP leads to the activation 
o f protein kinase A (PKA) that rapidly phosphorylates CREB at Serl33(Gonzalez 
and Montminy, 1989). The Seri 33 is located in an area o f CREB that is referred 
to as a the phosphorylation box, which is flanked by glutamine-rich amino acids 
that act as a transcriptional activation domain(Latchman, 2007). Upon 
phosphorylation of S eri33, CREB undergoes a structural change that allows it to 
activate transcription (Fig 1.6). CREB Seri33 phosphorylation is considered to be 
the key event that mediates the initiation of transcription since mutation of Seri 33 
to alanine abolishes transcription(Gonzalez and Montminy, 1989).
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Figure 1.5 Transcription factor activation mechanisms
Mechanisms o f transcription factor activation from an inactive to an active form 
by posttranslational changes, a) Ligand-mediated conformational change b) 
Removal o f  an inhibitory protein c) Protein modification d) Transcription factor 
stabilization in order not to get degraded (modified from (Latchman, 2007)).
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Figure 1.6 CREB activation
The ability o f DNA-bound CREB to activate transcription is produced by the 
cyclic-AMP dependent activation o f  PKA, which phosphorylates the CREB 
protein resulting in its activation (modified from (Latchman, 2007)).
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1.6 CBP and p300 transcriptional activity
As mentioned in section 1.5.2 the phosphorylation of CREB on Ser 133 activates 
transcription. To identify the mechanism of this effect, Chrivia et al. screened a 
cDNA expression library with Ser 133 phosphorylated CREB in order to identify 
proteins that would interact with phosphorylated CREB. This screen resulted in 
the isolation o f cDNA clones encoding CREB binding protein (CBP)(Chrivia et 
al., 1993). CBP is a 265 kDa co-transcription factor that binds to CREB only in its 
phosphorylated form (Fig 1.7) (Goodman and Smolik, 2000). CBP binding only to 
phosphorylated CREB suggested that CBP plays a role in the ability of CREB to 
activate transcription. In agreement with this, treating cells with antibodies to 
CBP prevented gene transcription in response to cAMP, indicating the importance 
of CBP for this effect(Giordano and Avantaggiati, 1999).
CBP displays great homology to another nuclear protein, p300, which was 
isolated independently from CBP (Eckner et al., 1994). Despite their high 
similarity no link was made between CBP and p300, until 1994. It is now known 
that CBP and p300 have similar functions as extremely versatile transcriptional 
co-activators(Arany et al., 1994). CBP and p300 (CBP/p300) were found to play a 
double role in gene transcription: 1) CBP/p300 link between DNA-binding 
transcription factors and the basal transcription machinery, providing a scaffold 
for transcription factor interaction 2) CBP/p300 modify histones by acetylation of 
specific lysine residues. (Fig 1.7)(Victor et al., 2002). Thus CBP/p300 were 
shown to bind to several components of the basal transcription machinery and 
CBP/p300 have been identified as part of the RNA polymerase II protein 
complex(Neish et al., 1998). Moreover, CBP/p300 were shown to have a HAT
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domain and were shown to acetylate histone, which is associated with 
modifications o f  chromatin structure and an increase in gene transcription (section 
1.2.1). Given the high structural and functional homology o f  CBP and p300, for 
the purposes o f  this thesis these proteins will be referred to  as CBP/p300. 
Nevertheless, when reviewing studies conducted on only one member o f  the 
family, reference is made only to the family member under study.
Figure 1.7 CBP association with the basal transcription machinery
CBP/p300 are recruited to act as bridge between DNA-bound phosphorylated 
CREB and the basal transcription machinery located at the start site o f  
transcription. In addition CBP/p300 act as a histone acetyhransferase, making the 
chromatin more accessible (figure was modified from (Lodish H., 2000)).
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1.6.1 CBP/p300 interactions and functions
Although CBP was originally identified as a co-activator for CREB, it was later 
shown that CBP or p300 are important co-activators for a variety o f factors, such 
as p53, MyoD, API, nuclear receptors and many other proteins (Fig 1.8). It was 
also shown that CBP/p300 bind with TBP, TFIIB, TFIID and RNA polymerase II, 
demonstrating their role in recruiting RNA polymerase II holoenzyme (Dallas et 
al., 1997; Kee et al., 1996). In addition, both CBP/p300 were shown to play a 
critical role in cardiac hypertrophy (Gusterson et al., 2003) and were demonstrated 
to be essential for modulating processes such as Gl-S phase transition in the cell 
cycle(Ait-Si-Ali et al., 2000).
The interaction of CBP/p300 with an array of transcription factors that are 
involved in different aspects of gene regulation, such as STAT, NFkB and API, 
places CBP/p300 at the cross roads of a range of signalling pathways in the cell. 
Thus, this suggests that CBP/p300 have a vital role in a variety of cellular 
functions (Fig 1.9)(Goodman and Smolik, 2000). The relatively low abundance of 
CBP/p300 in the cell means that different signalling pathways compete for 
CBP/p300, which results in mutual antagonism between different competing 
pathways. An example of this is the growth promoting effect of the API pathway 
compared to growth arresting effect of the p53 pathway(Avantaggiati et al., 1997; 
Kamei et al., 1996).
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Figure 1.8 CBP/p300 organisation and interactions
Interacting proteins are shown at the top o f  the figure; functional domains are 
depicted below. Many known interactions are not included due to space 
limitations (figure was modified from Goodman 2000(Goodman and Smolik,
2000)).
Figure 1.9 CBP/p300 interactions with transcription factors and the 
signalling pathways that activate them.
(modified from (Latchman, 2007)).
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1.6.2 CBP/p300 domain structure
In recent years several important amino acid domains have been identified in 
CBP/p300, as shown in Fig 1.8. These domains were found to be involved in 
transcription, activation or repression and protein-protein interaction. The N- 
terminal o f CBP/p300 contains an LXXLL sequence motif, in which L represents 
leucine and X represents any amino acid. LXXLL. The LXXLL motif has been 
found to be necessary and sufficient for ligand-dependent interactions with the 
nuclear receptor ligand binding domain(Heery et al., 1997). In addition, the 586- 
665 aa region of CBP/p300, referred to as KIX, was found to bind to 
phosphorylated CREB. KIX binds to the kinase inducible domain o f CREB and 
other transcription regulating proteins(Radhakrishnan et al., 1997). However, not 
all CBP domains are associated with gene activation. The 999-1057 aa region was 
shown to repress CBP activity through modification by SUMO-1 (Kuo et al., 
2005).
C-terminally from this domain, a bromodomain (1104-1176 aa) and a HAT 
domain have been described. The short bromodomain region binds acetylated 
lysine residues whereas the HAT domain, which occupies a central portion of 
CBP/p300, is involved in histone and non histone protein acetylation(Imhof et al., 
1997). Importantly, a growing number of molecules, other than histones, were 
shown to be acetylated by CBP/p300. An important example o f non-histone 
acetylation is the acetylation of p53 by p300, which increases the DNA-binding 
activity o f p53(Gu and Roeder, 1997).
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Moreover, CBP/p300 have three zinc finger motif domains, the first domain is 
located between 346-432 aa and binds several interacting factors. The second and 
third zinc finger regions lie in the HAT domain of CBP/p300 and were found to 
be necessary for CBP, but not p300, HAT activity(Bordoli et al., 2001a). 
Importantly, despite their structural role, none of these zinc finger motif domains 
make CBP/p300 a DNA binding protein. Lastly, both the N- and C-terminus of 
CBP/p300 were shown to contain an activation domain which were shown to 
increases the assembly of the transcriptional machinery (Kalkhoven, 2004).
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1.6.3 CBP/p300 post-translational modifications
Accumulated evidence demonstrated that cellular signals can affect CBP directly 
and thereby modify transcriptional responses without affecting CREB 
phosphorylation. Numerous kinases have been suggested to be involved in such 
processes. The cell cycle-regulated cyclin E-Cdk2 complex, for example, was 
demonstrated to phosphorylate CBP in v//ro(Banerjee et al., 1994) and thereby 
increase CBP HAT activity(Ait-Si-Ali et al., 1998). Moreover, several papers 
suggested that CBP is regulated by PKA, which was shown to phosphorylate CBP 
and increase CBP-dependent transcriptional response(Chrivia et al., 1993). 
Calcium-dependent pathways can equally trigger CBP phosphorylation, since 
CaMKIV was shown to phosphorylate CBP and increase its activity (Chawla et 
al., 1998). Furthermore, the MAPK family was also demonstrated to 
phosphorylate CBP(Janknecht and Nordheim, 1996), which was shown to 
increase CBP HAT activity(Ait-Si-Ali et al., 1998). In PC 12 cells, NGF increases 
the transcriptional activity o f CBP in a p42/p44 MAPKs-dependent manner (Liu 
et al., 1998). Subsequent studies reported that p44MAPK could phosphorylate 
CBP in vitro and suggested that this modification increased CBP HAT 
activity(Ait-Si-Ali et al., 1999). Additionally, CCAAT/enhancer-binding protein 
(C/EBP) family members were shown to recruit CBP and trigger its 
phosphorylation(Kovacs et al., 2003). It was therefore proposed that CBP 
phosphorylation might induce HAT function by changing the intermolecular 
conformation of CBP.
On the other hand, phosphorylation at serine 89 residue of p300 by PKC at was 
demonstrated to reduce p300-dependent transactivation and that this reduction is
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probably as a result of a reduction o f the interaction o f p300 with specific 
transcription factors(Yuan and Gambee, 2000). However, PKC phosphorylation at 
the serine 436 residue of CBP was found to enhance the ability of CBP to be 
recruited by AP-1 and Pit-1 transcription factors, and thus increase gene 
transcription(Zanger et al., 2001). Thus, this serine 436-residue phosphorylation 
o f CBP allows it to preferentially active different pathways under different 
conditions.
Moreover, CBP/p300 are modified by methylation on specific arginine residues 
that is essential for stabilizing the structure o f the KIX domain. This CBP/p300 
methylation was found to affect CBP/p300 ability to bind to some of the 
transcription factors with which they interact. Thus, CBP/p300 methylation 
abolishes their ability to bind to the CREB factor but has no effect on the ability 
of CBP/p300 to bind to nuclear receptors(Xu et al., 2001). Hence, the 
competition between different transcription factors for binding CBP/p300 can be 
altered by modification of the co-activator.
1.6.4 CBP/p300 in embryogenesis
Homozygous p300'A knock-out mice die early in embryogenesis, with lethality 
occurring between embryonic day 9 and 11.5. Several different factors seem to be 
involved in the lethality o f the knockout mice as they display defects in cell 
proliferation, heart development and closure o f the neural tube. Due to the early 
death o f p300A mice, it is not possible to observe the influence o f p300 deficiency 
on later events in embryogenesis, which may also be critically dependent on p300 
function(Yao et al., 1998). Moreover, heterozygous p300+/' mice also die in utero,
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suggesting that the normal dosage of p300 is limiting. In addition, while p300 
heterozygotes have an increased incidence of lethality, CBP heterozygotes are 
viable(Partanen et al., 1999; Tanaka et al., 1997).
Mice with homozygous CBP mutations in mice are not viable and they display 
similar defects to mice lacking p300(Kung et al., 2000; Oike et al., 1999b; Yao et 
al., 1998). However, while p300'7' knockout mice exhibit abnormal heart 
formation, CBP'7' mice show normal heart formation. Additionally, the CBP+/' 
/p300+/' double heterozygote mice are also embryonic lethal, which supports the 
idea that critical events in development are sensitive to the overall CBP and p300 
gene dosage. This data suggests that CBP and p300 exert certain common 
embryonic survival functions and that the combined dose of CBP and p300 is 
critical for mouse embryonic development. On the other hand, overexpression of 
CBP in Drosophila embryos was found to be lethal demonstrating the tight 
regulation o f CBP/p300 (Marek et al., 2000).
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1.7 CBP and p300 and their roles in diseases
1.7.1 CBP and Rubinstein-Taybi Syndrome
Rubinstein-Taybi syndrome (RTS) is a genetic disease characterised by mental 
retardation, broad thumbs and toes, short stature, distinctive facial features, 
skeletal abnormalities and increased risk o f cancer(Rubinstein and Taybi, 1963). 
The incidence of RTS is estimated at 1/125,000 births and accounts for 1/300 
cases of institutionalized mentally retarded people. Originally, the disease was 
found to be caused by mutations in CBP (Petrij et al., 1995). CBP has been found 
to be involved with 50% of RTS cases (Bartsch et al., 2005) and a very small 
percentage carry mutations in p300 (Roelfsema et al., 2005). The types of CBP 
mutations associated with RTS include missense mutations, translocations, 
inversions and microdeletions.
Wide variation exists in the severity of the mental deficiency and other clinical 
manifestations of RTS. The intelligence level o f different RTS patients varies 
between the low IQ scores o f 25 to 79. Other variable findings are congenital 
heart defects, renal abnormalities and failure o f the testes to descend into the 
scrotum (cryptorchidism).
The variable clinical manifestations seen in RTS could be due to two different 
mechanisms of CBP dysfunction. The first mechanism of CBP dysfunction is 
haploinsufficiency, where there is only one functional copy of the CBP gene, 
which is not sufficient to produce enough protein to reach a wild-type condition. 
The second mechanism is a dominant-negative mutation of CBP, where abnormal
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product derived from the mutant allele inhibits the wild-type product. To date, 
evidence supporting both mechanisms has been reported(Alarcon et al., 2004; 
Oike et al., 1999a). Thus, it seems likely that both mechanisms of CBP 
dysfunction can play a role in the development of RTS phenotypes.
In mice, a heterozygous deletion leads to a phenotype similar to RTS, which 
includes deficits in various forms of long-term memory(Alarcon et al., 2004; Oike 
et al., 1999b). Importantly, in RTS cases where CBP is truncated it was shown 
that CBP lacks part of its HAT region, thus impairing its ability to acetylate 
histones(Murata et al., 2001). Additionally, some CBP missense mutations were 
also shown to annul CBP HAT activity, suggesting that two sets o f functional 
CBP HAT are needed to prevent RTS. Moreover, mutations that are found outside 
of the HAT domain might also contribute to diminished HAT activity. This is due 
to the regulation of the HAT domain o f CBP by different regions in CBP, such its 
bromodomain.
The data above demonstrate that CBP is highly involved in RTS. It is hard to 
identify if RTS phenotypes arise from either CBP dysfunction in the nervous 
system during development or CBP dysfunction in neurons during adulthood. To 
address this issue, Korzus et al. generated inducible dominant-negative CBP 
(CBP[HAT-]) mice(Korzus et al., 2004). The CBP[HAT-j line-inducible CBP has 
two amino acid substitutions, which eliminate CBP HAT activity. The CBP[HAT- 
] induced adult mice exhibited normal short-tem memory while LTM was 
impaired. Interestingly, Korzus et al. were able to rescue the impaired LTM by 
suppression of the transgene expression and by administration of a histone
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deacetylase inhibitor, suggesting that a pharmacological manipulation of HAT 
activity might provide a possible therapeutic method for treating RTS symptoms. 
Moreover, this might suggests that RTS LTM defects are as a result of CBP 
dysfunction in adult brain and not as a product of abnormal brain development.
1.7.2 Huntington’s disease
Huntington’s disease (HD) is an autosomal dominant neurological disease 
characterized by movement dysfunction and cognitive abnormalities. HD, which 
affects 1/ 1 0 , 0 0 0  people, is a dominant genetic defect is caused by expansion of an 
unstable CAG repeat in the huntingtin gene (Htt) resulting in a greatly expanded 
polyglutamine (polyQ) tract in the protein it encodes(Gusella and Macdonald, 
2007). It is seems that in HD patients that tracts of 37 or more CAGs cross a 
pathogenetic threshold while normal individuals have 7-34 CAG repeats(Gusella 
and MacDonald, 2000). Despite its size (348kDa), Htt is soluble and its wild-type 
form was found to play a role in embryogenesis(Cattaneo et al., 2001), vesicular 
transport(Trushina et al., 2004) and in addition it may possess neuroprotective 
activity(Zhang et al., 2006).
The well-characterized HD mice models (Mangiarini et al., 1996; Schilling et al., 
1999; Yamamoto et al., 2000) have greatly enhanced our understanding o f the 
disease, however the mechanism by which Htt elicits its toxic effect is unclear. 
Several mechanisms such as oxidative damage, mitochondrial dysfunction and 
transcriptional deregulation were proposed as pathogenic mechanisms(Browne 
and Beal, 2004).
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One mechanism by which Htt mutants deregulate transcription is by interaction 
with CBP(Nucifora et al., 2001). Colocalization of CBP with polyQ aggregates 
has also been observed in cells in culture, transgenic mice, and postmortem HD 
brain tissue(McCampbell et al., 2000; Nucifora et al., 2001). Moreover, not only 
did the Htt mutant protein bind to CBP, it also sequesters CBP into protein 
aggregations (Fig 1.10)(McCampbell et al., 2000; Nucifora et al., 2001). In 
addition histone acetylation is reduced in the R6/2 mice, which might be a result 
of the loss of soluble levels of nuclear CBP(Ferrante et al., 2003). Since the 
amounts of CBP in the cell are limiting, this prevents its binding to transcriptional 
activators and therefore causes disease(Nucifora et al., 2001). Furthermore, 
experiments in Drosophila polyQ disease models demonstrated that the 
progression o f the disease is inhibited by HDAC inhibitors and thus suggest that 
the CBP HAT domain is involved in the disease(Steffan et al., 2001).
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Figure 1.10 Mechanisms leading to CBP loss of function
CBP loss o f  function has been observed in different contexts o f  neurological 
disorders. First, RTS outcomes from a mutation on an allele o f  the CBP gene that 
results in decreased amounts o f  functional CBP protein. Second, in several cases 
o f polyQ diseases, decrease in the amount o f  available CBP can be achieved by 
sequestration o f  the protein by mutated polyQ proteins, forming aggregates in the 
cytoplasm or the nucleus (figure modified from (Rouaux et al., 2004)).
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1.8 Alzheimer’s disease
Alzheimer’s disease (AD) is the most common form of dementia, affecting 
approximately 5% of the population over the age of 65 years in Europe(Lobo et 
al., 2000). Extensive literature suggests that AD begins as a synaptic disorder that 
progressively involves larger areas of the brain, resulting in deteriorating 
memory (Cullen et al., 1997; Itoh et al., 1999; Masliah, 1995; Vitolo et al., 2002; 
Walsh et al., 2002).
In this regard, p-amyloid (Ap), a major component o f the amyloid plaques that 
constitute a neuropathologic hallmark of the disease(Fig 1.11), has been found to 
inhibit Long-term potentiation (LTP), a physiologic correlate of memory (Cullen 
et al., 1997; Vitolo et al., 2002). The amyloid plaque is a heterogeneous class of 
protein aggregates with p-pleated structure. Amyloid plaques are varyingly 
composed o f compact or non-compact amyloid, and can be associated with 
degeneration of nearby neuronal cell processes(Dickson, 1997). The amyloid 
deposits are composed o f straight, unbranching fibrils of 6 - 1 0 nm at the 
ultrastructural level. Seminal work by Glenner and Wong identified these deposits 
to be composed mostly of the aggregated 4 kDa Ap protein(Glenner and Wong, 
1984). Ap is heterogeneous in size, but the predominantly Ap is found as Ap40- 
42(Iwatsubo et al., 1994). Moreover, control subjects with high plasma Ap42 
levels have an increased chance of developing AD(Mayeux et al., 2003) (Mayeux 
et al 1999). Ap is the proteolysis product of a larger precursor protein, the 
amyloid precursor protein (APP), which in its mutant form has been found to 
cause the familial Alzheimer’s disease (FAD)(Kang et al., 1987).
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The next two AD associated genes discovered were presenilin (PS) 1 and 
PS2(Levy-Lahad et al., 1995; Sherrington et al., 1995) and these were found to 
be the primary cause of familial AD (FAD)(Czech et al., 2000). PS1 is a part of 
the y-secretase complex which is responsible for the cleaving of APP, leading to 
the increased production of A|342 peptide(Takahashi et al., 1999) suggesting a 
toxic gain-of-function pathogenic mechanism.
Studies on human Ap-producing transgenic (Tg) mice have often revealed 
significant deficits in hippocampal basal synaptic transmission (BST) and/or LTP 
(for a review see (Sant'Angelo et al., 2003)). Furthermore, recent studies indicate 
that the expression o f FAD-linked mutant PS1 in neural and primary cell lines 
leads to sensitivity to apoptosis, implying that neurotoxicity by FAD genes may 
play a role in the pathogenesis o f AD(Czech et al., 1998; Hashimoto et al., 2004; 
Weihl et al., 1999; Zhang et al., 1998).
Another hallmark, in addition to the amyloid plaques, of AD is the formation of 
neurofibrillary tangles (Fig l.ll)(N FTs). In the mid 1980s, a number of 
laboratories discovered that the main protein composing NFTs was the 
microtubule-associated protein, tau(Grundke-Iqbal et al., 1986; Kosik et al., 
1986). In Alzheimer’s, tau deforms and loses its ability to support the cell, 
eventually aggregating into NFTs. Moreover, NFTs occur in the regions of the 
brain responsible for the various cognitive domains that are compromised during 
the course of AD and the density of tau inclusions correlating well with regional 
and global aspects of cognitive decline(Ghoshal et al., 2002; Mitchell et al., 
2002). However, since this thesis focuses mainly on the on PS1 and its 
association with CBP, the tau theory will not be discussed further here.
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Figure 1.11 Alzheimer’s amyloid plaques and neurofibrillary tangles
The formation o f  amyloid plaques and neurofibrillary tangles are thought to 
contribute to the degradation o f  the neurons in the brain and the subsequent 
symptoms o f  Alzheimer's disease (Fig was taken from Alzheimer’s Health 
Assistance Foundation website www.ahaf.org).
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1.8.1 Genetics and risk factors for AD
AD is genetically complex and heterogeneous disorder. The prevalence of AD 
doubles every five years after 65 up to 90 and then remains stable. The most 
important risk factor for the development of AD is increasing age(Qiu et al., 
2005). Other risk factors include family history of dementia, hyper and 
hypotension, high cholesterol, head trauma, low physical activity, obesity, low 
education, anaemia and heart failure(Atti et al., 2006; Kivipelto et al., 2001; 
Kivipelto et al., 2005; Qiu et al., 2006). As mentioned above, mutations leading 
to predominantly early onset o f FAD have been characterized in three genes: APP 
on chromosome 21, PS1 on chromosome 14 and PS2 on chromosome 1. These 
mutations are inherited in an autosomal dominant manner with nearly 1 0 0 % 
penetrance(Selkoe, 2001). However, mutations in these three genes account for 
less than 5% of all AD cases. The rest of the 95% of AD patients are by and large 
sporadic late onset cases with no recognizable pattern of classical mendelian 
inheritance. Sporadic AD patients share similar clinical and neuropathological 
features as the autosomal dominant AD patients, but the underlying genetic 
mechanism appears to be more complex.
Interestingly, in Down syndrome (trisomy 21), the triplication leads to 
overexpression of genes located on chromosome 21, including the APP gene. This 
results in the development of neuropathological changes similar to AD at the age 
o f 40 years. At an age as early as 20-30 years these individuals develop amyloid 
plaques and later in life also neurofibrillary tangles(Mann et al., 1986).
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1.8.2 Neuropathology of AD
Clinical symptoms are observed only late in the course of the disease, and the 
steady worsening of symptoms reflects the gradual development of brain 
destruction. This begins in a few limbic areas of the cerebral cortex, and then 
spreads in a predictable, non-random manner across the hippocampus, the 
neocortex and a number of subcortical nuclei (Fig 1.12) (Braak and Braak, 1995). 
The limbic system is involved in maintaining the functions o f memory and in 
establishing emotional aspects of personality. Atrophy o f these regions leads to 
dementia.
During normal aging, changes occur in the anatomy of the brain. These alterations 
include an overall reduction in brain volume and weight, which are due to 
neuronal cell loss(Anderton, 1997). AD is a pathological form of aging and there 
is significant loss of large cortical neurons in AD brains compared to normal 
brains(Terry et al., 1981). Mounting evidence suggests that AD begins with subtle 
alterations of hippocampal synaptic efficacy prior to neuronal 
degeneration(Selkoe, 2002). Accordingly, the earliest symptoms appear to 
correlate with dysfunction of the cholinergic and glutamatergic synapses(Selkoe,
2002). Definitive diagnosis of AD is possible only upon autopsy.
As mentioned above, the two specific histopathological hallmarks of AD are the 
extracellular amyloid plaque and the intracellular NFTs. However, plaques and 
tangles are regularly found in autopsied brains of cognitively normal elderly 
individuals, this probably indicates the long preclinical phase o f AD rather than 
plaques and tangles being normal in aging.
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Figure 1.12 Major structures of the limbic system
Figure was taken from Le Moyne College website: http://web.lemovne.edu/
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1.8.3 APP processing
A central feature of APP biology is its the proteolysis. Upon synthesis, the APP 
molecule is proteolytically processed by so-called secretases. Three primary 
proteolytic cleavage sites were characteristics in APP. Two proteolytic cleavage 
sites were found close to the membrane and one site within the transmembrane 
domain and are termed a, p and y cleavage sites (Fig 1.12). All cleavages are 
catalyzed by separate enzymes complexes referred to as a-, p- and y-secretases. 
The a  and p cleavages are separate events and each release a large extracellular 
domain o f the protein, differing in size by only 17 amino acids at the c-terminus. 
The rest of APP is tethered to the membrane and is referred to as the c-terminal 
fragment, C99 for the P and C83 for the a-generated product. The transmembrane 
cleavage event catalyzed by y-secretase occurs subsequent to a  or p cleavage at 
several sites in close proximity within the c-terminal fragment sequence. Thus, 
after p cleavage, C99 may be processed by y-secretase, which require the presence 
of PS proteins(Herreman et al., 2000), to generate the predominant Ap40 or Ap42 
fragments, as well as fragments spanning Ap39 and Ap43, together with the 
remaining C-terminal tail. Similarly, after a  cleavage, C83 can be processed by y- 
secretase to generate p3 fragment, with the same C-terminal fragments.
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Figure 1.13 APP processing
In the left o f  the figure, APP is processed by P-secretase to generate C99. In the 
non-amyloidogenic pathway, a-secretase generates C83. The C-terminal 
fragments o f both pathways are processed by y-secretase generating Ap or p 3 .
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1.8.4 Amyloid precursor protein
During the past few years, progress in understanding the transport and the 
proteolytic processing of APP has provided insights into the molecular basis of 
FAD. The cloning of the gene that encodes APP(Kang et al., 1987) was made 
possible by the purification and sequencing of its Ap fragment from the 
micro vascular amyloid deposits of AD and Down’s syndrome patients(Glenner 
and Wong, 1984). APP comprises a group of ubiquitously expressed polypeptides 
whose heterogeneity arises from both alternative splicing and post-translational 
processing(Selkoe, 1994). Despites its importance in the development of AD, 
deletion of the gene in mice results in neither early mortality nor appreciable 
morbidity.
The lack of a vital consequence of APP deletion in vivo may result from 
mammals expressing proteins that are closely homologous to APP, the amyloid 
precursor-like proteins (APLPs)(Wasco et al., 1992), but which do not contain the 
Ap sequence. Thus, the prime function(s) o f the molecule in vivo remain vague. 
However, functions that have been described in vitro include enhancement of cell- 
substrate adhesion, cholesterol metabolism and cognitive processes(Tumer et al.,
2003). However, no evidence has emerged that a basic cellular function of APP is 
lost in AD patients; instead, APP mutations seem to act by a gain of function 
mechanism, mostly the increased production of the cytotoxic Ap fragment.
1.8.5 Presenilin 1
PS1 is expressed in most human tissues including embryonic and adult
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brain(Kovacs et al., 1996; Lee et al., 1996). The highest concentrations in the 
brain are detected, according to in situ hybridization, within the neurons of the 
hippocampus, entorhinal cortex and low traces of transcript are also found in 
white matter glial cells. The hydrophobic PS1 protein consists of 467 amino acids 
and it is shown to span eight times the membranes(Hardy, 1997) (Fig. 1.14). The 
N- and C termini as well as the large hydrophilic loop between TM6  and TM7 are 
orientated towards the cytoplasmic side and are therefore available for interactions 
with various cytoplasmic proteins (Zhang et al., 1998). PS1 protein is mainly 
located within the ER, however, PS1 immunoreactivity has showed it can also be 
found in Golgi apparatus as well as plasma membranes and nuclear kinetochores.
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Figure 1.14 PS1 molecular model
The eight putative transmembrane domains are depicted as open barrels 1-8, with the amino- and carboxy-terminal domains 
and large loop domain projecting into the cytoplasm. Residues associated with mutations found in familial Alzheimer's disease are coloured as 
indicated in the key. 'Endoproteolysis' indicates the approximate site o f the imprecise cleavage o f the molecule. (Figure was modified 
from(Tandon and Fraser, 2002)).
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1.8.6 Functions of PS1
A major function of the PSs is their role within the y-secretase complex, and in 
addition to APP, this complex processes a variety of other targets, for example 
Notch, LRP and Cadherin family members (Koo and Kopan, 2004). These 
additional targets are localised to detergent soluble membrane domains, indicating 
that these processing events are distinct from APP processing(Vetrivel et al., 
2005). Moreover, several lines of evidence indicate that the functions of PS1 are 
related to apoptosis and the processing and trafficking of membrane proteins. In 
addition, the mutant o f PS 1 is known for its involvement in the APP processing, 
and its responsibility for the increased production and deposition of the 
amyloidogenic Ap42(Citron et al., 1997; Scheuner et al., 1996). The following 
description of the functions of the PSs is by no means exhaustive, but provides an 
overview of perhaps the most relevant roles of this protein.
Notch processing
Studies conducted on the Caenorhabditis elegans homologue of PS1, SEL-12, 
and with PS1 knockout mice, has shown that PS1 may be involved in the 
processing and trafficking of membrane-bound proteins including the Notch 
receptor(Levitan and Greenwald, 1995; Wong et al., 1997). PS1 protein 
deficiency and the aspartate mutations in TM6  and TM7 of PS1 gene block the 
endoproteolytic cleavage of Notch. Notch intracellular cytoplasmic domain 
(NICD), which is released from the Notch after endoproteolysis, translocates to 
the nucleus, where it is needed for modifying transcription o f specific genes, 
which regulate cell-fate during development(Schroeter et al., 1998).
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Wnt signalling
The Wnt family are a group of extracellular glycoproteins that regulate 
homeostasis and development. Wnt signalling leads to the stabilisation of p- 
catenin and induction of gene expression(Nelson and Nusse, 2004). Thus, Wnt 
signalling increases cytosolic p-catenin, which translocates to the nucleus where it 
activates transcription of genes such as Cyclin D l.
WT PS1 interacts with components of the Wnt signalling cascade. It binds to p- 
catenin and negatively regulates both its stability and transcriptional 
activity(Killick et al., 2001). Moreover, both PS and p-catenin can be 
phosphorylated by p35/Cdk5(Lau et al., 2002; Munoz et al., 2007) and this may 
regulate their binding (Kesavapany et al 2001). On the other hand, PS1 mutations 
have reduced ability to bind to P-catenin, thus leading to increased p- 
catenin(Killick et al., 2001).
In addition, Wnt signalling may function in regulation o f cognitive processes. 
Thus, the deregulation of endogenous p-catenin is observed in rats injected with 
preformed Ap fibrils, and there is also evidence of neurodegeneration and 
behavioural impairments (De Ferrari et al., 2003).
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1.9 CBP and Alzheimer’s disease
It has been shown that wild type PS1 cleaves the transmembrane protein N- 
cadherin to release an intracellular C-terminal fragment. In turn, this fragment has 
been shown to bind to CBP and promote rapid proteasomal degradation, which 
downregulates CBP function (Marambaud et al., 2003). Moreover, it has been 
demonstrated that the mutant forms of PS1 found in FAD cannot cleave N- 
cadherin and therefore fail to generate the C-terminal fragment that will lead to 
CBP degradation. This suggests that the mutation in PS1 would result in enhanced 
levels o f CBP and that CBP over-expression might be toxic.
It has also been shown that introduction of the FAD mutant PS-1/L286V caused 
dysregulation of TCF/(3-catenin signalling, which has a central role in neuronal 
differentiation and proliferation. Thus, the PS-1/L286V mutant inhibits neuronal 
differentiation and the TCF/p-catenin/CBP interaction is involved in the 
dysregulation caused by the PS-1/L286V FAD mutant(Teo et al., 2005). 
However, it was shown that despite the homology high homology between p300 
and CBP, the TCF/(3-catenin/p300 interaction was not involved in the effect of 
PS-1/L286V mutant.
In contrast, previous investigations o f normal presenilin function revealed a 
contradictory role o f a PS 1-CBP interaction in neurodegeneration. Thus, PS 1 and 
2 conditional double knockout mice showed reductions in CBP levels and in 
CRE-dependent gene expression in the cerebral cortex, which is likely to 
contribute to subsequent neuronal degeneration(Saura et al., 2004). Interestingly, 
studies in cultured neurons show that A(342 inhibits activity-induced
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phosphorylation of CREB, which serves as an essential step for CREB-CBP 
signaling(Gong et al., 2004). Moreover, it was shown that CBP loss takes place 
during neuronal death in models relevant to AD. During their experiments, 
Rouaux et al. demonstrated that when neurons were committed to die through the 
use o f an antibody directed against the extracellular fragment of the APP, they 
displayed both CBP loss and histone deacetylation(Rouaux et al., 2003). Thus, 
reduced activity of the CREB-CBP pathway might offer a new possible AD 
pathogenic mechanism.
Saura et al. global reduction in CRE-dependent gene expression caused by loss of 
PS function is in direct disagreement with Marambaud et al. In their report 
Marambaud et al. showed reduced N-cadherin processing in cultured PS1 null 
cells was found to cause decreased cytoplasmic retention of CBP and increased c- 
fos expression, which is a gene that is induced by CBP(Marambaud et al., 2003). 
In contrast, Saura et al. examined the expression o f multiple CRE-dependent 
genes, including c-fos, by quantitative methods in the adult cerebral cortex, and 
identified a consistent reduction in CRE-dependent transcription in the absence of 
PS function. Moreover, Saura et al. identified a parallel reduction in both nuclear 
and cytoplasmic CBP levels as a consequence of PS inactivation(Saura et al.,
2004). In view of this contradiction, it would be interesting to further investigate 
the potential role of CBP in Alzheimer's disease.
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1.10 Aims and objectives
The closely related CBP and p300 co-activator molecules play a key role in 
memory and learning. To date, the role of CBP and p300 in AD, as it shown in the 
literature, is unclear and contradictory. The aim o f this thesis was to investigate 
the role of CBP and p300 in AD in three main steps:
1. To look at the effect o f WT and mutant PS1, a known mutation associated 
with AD, on the transcriptional activity of CBP and p300, and investigate 
the signalling pathways involved using chemical inhibitors. In addition, to 
examine the specific regions o f CBP and p300 that are involved in 
changes o f activity induced by WT PS1.
2. To use antisense CBP to investigate the effect o f inhibiting CBP in the 
stimulus response to WT PS1 using c-fos, one of the genes induced in the 
brain by CBP, which is involved in memory formation, luciferase 
expression. Additionally, to study the involvement of CBP histone 
acetyltransferase activity in the stimulus response to WT PS1.
3. To determine whether inhibitors of histone de-acetylation re-establish 
normal synaptic function and memory in the Alzheimer’s disease mouse 
model.
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Chapter 2
2 MATERIALS AND METHODS
2.1 Laboratory reagents
2.1.1 General suppliers
General laboratory chemicals were of analytical grade and purchased from the 
following companies: Sigma-Aldrich Corporation, Poole Dorset, UK; VWR 
International Ltd., Lutterworth, Leicestershire, UK; Hoffmann-La Roche Ltd, 
Basel, Switzerland. Phosphate buffered saline (PBS) was made using PBS tablets 
(1 tablet in 500ml ddH20) from Invitrogen Ltd., Paisley, UK. All solutions were 
made with Millipore water and autoclaved where necessary. General laboratory 
plasticware was purchased from VWR International Ltd., Dorset, UK and 
Eppendorf UK Ltd., Cambridge, UK.
2.1.2 Bacterial reagents
Bacto®- Yeast extract, Bacto®- Tryptone and Bacto® Micro-agar for bacterial 
growth medium were from Duchefa Biochemie, Haarlem, Netherlands. XLI blue 
E.eali cells were purchased from Stratagene, La Jolla, California, USA.
2.1.3 Molecular reagents
Restriction and modifying enzymes and buffers were purchased from Promega, 
Southampton, UK. QIAprep Mini prep and Maxi DNA prep kits were from 
Qiagen Ltd, Crawley, UK. DNA sequencing was performed by MWG-Biotech 
AG, Ebserberg, Germany.
75
2.1.4 Western blotting reagents
Hybond™-c nitrocellulose membranes, protein molecular weight Rainbow™ 
marker, Enhanced Chemiluminescence system (ECL) and Kodak XOMAT 
imaging photographic film were purchased from Amersham Bioscience, Little 
Chalfont, Buckinghamshire, UK. 30% (w/v) acrylamidelbisacrylamide solution 
for polyacrylamide gels was obtained from Amresco Inc., Ohio, USA. 
Photographic developing and fixing chemicals were obtained from Xograph 
Healthcare Ltd., Tetbury, UK. Primary antibodies were purchased from Santa 
Cruz Biotechnology, Santa Cruz, CA, USA and Cell Signaling Technology, Inc., 
Danvers, MA, USA. Secondary antibodies were purchased from DAKO Ltd., 
Glostrup, Denmark.
2.1.5 Tissue culture reagents
FuGENE 6  Transfection Reagent was obtained from F. Hoffmann-La Roche Ltd, 
Basel, Switzerland. Tissue culture reagents were purchased from Gibco, Paisley, 
UK. Disposable sterile 0.2 pm filters were purchased from Millipore, Watford, 
UK. All cell culture flasks were obtained from Nunc UK and plasticware from 
Falcon, UK.
2.1.6 Assay reagents
Luciferase reagent and lysis buffer were purchased from Promega, Southampton, 
UK. BCA Protein assay kit was from Pierce, Rockford, USA.
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2.1.7 Equipment
Trans-Blot™ cell transfer tanks, Bio-Rad Laboratories Ltd., Hertfordshire, UK. 
Syngene light box, Syntopics Ltd., Cambridge, UK.
Bio-Rad GS-800 densitometer, Bio-Rad Laboratories Ltd., Hertfordshire, UK. 
TD-20/20 Luminometer, Turner Designs, Sunnyvale, California, USA.
Zeiss microscope, Carl Zeiss Microimaging, Inc., New York, USA.
BioRad GS800 Densitometer, Bio-Rad laboratories Ltd., Hertfordshire, UK.
Labsystems Multiskan RC Plate reader, Finland.
Leica TCS SPE confocal microscopy, Leica Microsystems, Mannheim, Germanny
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2.2 Cell culture
All cell culture work was carried out under sterile conditions in a laminar flow 
cabinet. Media and reagents were purchased sterile, autoclaved or filtered with 
0 .2 pm filters.
2.2.1 FI 1 cells
F l l  cells (F ll/E cR  cells) stably overexpress both EcR and RXR. F l l  cells are 
the hybrid of a rat embryonic day-13 primary cultured neuron with a mouse 
neuroblastoma NTG18. These cells are one of the best models for primary 
cultured neurons; they exhibit, without differentiation factor treatment, a number 
o f characteristics of primary neurons, including generation of action potentials. 
The cells were grown in Ham's F-12 plus 18% fetal bovine serum (FBS) and 
antibiotics (1% penicillin and streptomycin). F ll  cells were the kind gift o f I. 
Nishimoto, Department o f Pharmacology and Neurosciences, KEIO University 
School o f Medicine, Shinanomachi, Tokyo, Japan (Hashimoto et al., 2002).
2.2.2 Cell transfection
Cells were dissociated with incubations in Trypsin solution for 2 min and seeded 
at 7*104 cells/well in a 6 -well plate and cultured in Ham's F-12 plus 18% FBS for 
over night. Cells were then transfected with DNA using the FuGENE 6  reagent at 
a ratio (v/v) of 2 : 1  (according manufacturer protocol) and incubated overnight.
DNA plasmids used in transfections are summarised in Table 2.1. The 
propagation and isolations o f DNA plasmids are described in section 2.3.
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CBP plasmids Description Refe re nce/Sou rce
pGal4-(l-147) 
pGal4-CBP-( 1-460) 
pGal4-CBP-(721-1679) 
pGal4-CBP-( 1678-1843) 
pGal4-CBP-( 1844-1956) 
pGal4-CBP-( 1961-2039) 
pGal4-CBP-(2060-2179) 
pGal4-CBP-(2173-2288) 
pGal4-CBP-(2288-2441) 
pGal4-CBP-(Full length)
The pGal( 1-147) plasmid encoding the DNA binding domain of the 
yeast protein Gal4 was digested with Hindlll and Xbal, and the DNA 
fragment encoding Gal4 amino acods 1-147 subcloned into the 
plasmid Rc/RSV (Invitrogen). This plasmid, Rc/RSV Gal-(1-147), 
was used as a basis to construct the remaining chimeric proteins.
J. Chrivia, Vollum Institute, 
Oregon Health Sciences University, 
Portland, Oregon 97201, USA 
(Swope et al., 1996)
5xgal4-E2B TATA 
luciferase
Contains five copies of Gal4-binding site upstream of the TATA box 
from the viral E1B promoter, which is linked to the coding sequence 
of firefly luciferase. This plasmid was prepered by insertion of a 
Hindlll-BamHI DNA E1B TATA box from G5CAT into a plasmid 
containing the luciferase coding sequence.
R.A Maurer, Department of Cell 
and Developmental Biology, 
Oregon health Sciences University, 
Oregon, USA (Sun et al., 1994)
CBP full length Full length mouse CBP (2442 amino acids) was cloned into Rc/RSV 
(Invitrogen).
Y.Z. Liu, Institute of Child Health, 
London, UK.
CBP antisense Constructed by cloning CBP full-length (1-7326) into the BamHI site 
of bluescript SK (Stratagene) in the reversed orientation and 
subsequently cut the insert with Notl and Sail and inserting it into a 
pBI-G expression vector.
R.J. Gusterson, Institute of Child 
Health, London, UK.
Gal4-CBP HAT WT CBP was cloned into Hindlll/Notl site of pcDNA3 (Invitrogene) from 
pRc/RSV mCBP.
R. Eckner, Institute for Molecular 
Biology, University of Zurich, 
Winterthurerstrasse, Zurich, 
Switzerland (Bordoli et al., 2001b)
Gal4-CBP HAT WY Amino acids 1503-1504 replaced by alanine and serine
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p300 plasmids Description Reference/Source
pGa!4-p300 The pGal4-p300 fusion vector was made by inserting Gal4 1-147 
sequwnce into p300 cDNA at the position for the 19th amino acid and 
subcloning the fusion unit into the pcDNA (Invitrogene). The p300 
deletions were made from the pGal-p300 by digestion with restriction 
enzymes and re-ligation.
A. Giordano, Jefferson Cancer 
Institute and Department of 
Microbiology/Immunology and 
Pathology, Thomas Jefferson 
University, PA, USA (Yuan et al., 
1996)
pGal4-p300-( 1-743)
pGal4-p300-(1242-1737)
pGal4-p300-(964-1922)
pGal4-p300-( 1514-1922)
pGal4-p300-( 1737-2414)
pGal4-p300-( 1945-2414)
O ther plasmids Description Reference/Source
pIND WT PS1 PS cDNAs were digested with BamH I - EcoR I and subcloned into 
pIND plasmids
I. Nishimoto, Department of 
Pharmacology and Neurosciences, 
KEIO University School of 
Medicine, Shinanomachi, Tokyo, 
Japan (Hashimoto et al., 2002)
pIND M146L PS1
pcDNA3 WT PS1 This plasmids contain PS cDNAs that were subcloned in pcDNA Dr. G. Levesque, Molecular and 
Human Genetics Unit, CHUQ- 
Pavillon St-Fran9 ois d ’Assise, 
Canada
pcDNA3 Y115HPS1
pcDNA3 M146L PS1
pcDNA3 E318G PS1
pcDNA3 L392V PS1
c-fos-luciferase A 447 bp fragment containing the human c-fos promoter (from -405 
to +42 bp) was inserted into the pLucIAV vector upstream of the 
luciferase reporter gene
Dr. J.S Ramsdell, Center for 
Coastal Environmental Health and 
Biomolecular Research, NOAA- 
National Ocean Service, 
Charleston, SC, USA
TK-Renilla luciferase This contains the Renilla luciferase gene under the control of the 
minimal thymidine kinase promoter
Promega UK. Southampton, 
United Kingdom
Table 2.1 DNA plasmids.
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2.2.3 Stimulation of cells
PD 98059 (PD), a p42/p44 MAPK inhibitor, was dissolved in DMSO and used at 
a concentration of 25pM (Promega Corporation, Southampton, UK).
LY 294002 (LY), a PI 3-kinase inhibitor, was dissolved in DMSO and used at a 
concentration of 50pM (Promega Corporation, Southampton, UK).
SB 203580 (SB), a p38 MAPK inhibitor, was dissolved in DMSO and used at a 
concentration of lOpM (Promega Corporation, Southampton, UK).
Ponasterone A, which was employed as an ecdysone analogue (EcD), was then 
added 8 hr after transfection and incubated overnight (Invitrogen Ltd, Paisley, 
UK).
2.2.4 siRNA
siGENOME Non-Targeting siRNA #1 was purchased from Thermo scientific 
(Chicago, USA).
Presenilin 1 mouse siRNA was purchased from Santa Cruz Biotechnology, Santa 
Cruz, CA, USA.
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2.3 Propagation, purification and manipulation of plasmid DNA
All manipulations of bacterial cultures were carried out under sterile conditions. 
All media and glassware were autoclaved before use at 120°C, lOpsi for 20 
minutes, and sterile plasticware was used. Manipulations were carried out over a 
Bunsen burner flame to prevent contamination.
2.3.1 Transformation of E.coli
The E.coli strain XL 1-blue was used for the propagation o f plasmid DNA. XL1- 
blues were streaked on a plate of Luria Bertani (LB) Agar (1% (w/v) Bacto®- 
tryptone, 1% (w/v) NaCl, 0.5% (w/v) Bacto®-yeast extract, and 2% (w/v) 
Bacto®-Micro agar). 24 hours later a single colony was picked and used to 
inoculate 5mls o f LB medium (1 % (w/v) Bacto®-tryptone, 1% (w/v) NaCI, 0.5% 
(w/v) Bacto®-yeast extract). This starter culture was grown overnight in an orbital 
shaker at 37°C, 200rpm.
In order to allow transformation, bacteria must be made competent to allow entry 
of plasmid DNA. lOOpl of starter culture was used to inoculate 100ml of LB and 
cultured in the orbital shaker until the culture had an optical density 600nm of 0.4- 
0.5 units (between 4-6 hours). The cultures were then pelleted in sterile 50ml 
tubes by centrifugation at 2500g at 4°C for 10 minutes. The supernatant was then 
discarded and the pellets re-suspended in 5 ml ice cold lOOmM CaCl2 for 1 hour. 
The bacteria were then centrifuged as above and resuspended in 1ml ice cold 
lOOmM CaCl2 and incubated on ice for 1 hour prior to use.
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For transformation, lOOpl of competent cells were aliquoted into 1.5ml sterile 
microcentrifuge tubes, mixed with 1 pg of plasmid DNA and incubated on ice for 
10 minutes. The cells were then heat shocked at 42°C for 90 seconds and cooled 
on ice for 2 minutes. 800pl of LB medium was added and the cells incubated in 
an orbital shaker for 1 hour. The cells were then centrifuged at 145g for 1 minute 
at 20°C. 800pl o f supernatant was discarded and cells re-suspended in the 
remaining lOOpl. The cell suspension was then spread onto LB agar plates 
containing the appropriate selectable marker. Ampicillin was used at a 
concentration of 50pg/ml and cells were spread onto agar plates that were 
incubated at 37°C overnight and then stored for up to one month at 4°C.
2.3.2 Large scale plasmid DNA extraction from E.coli
Qiagen-tip 100 plasmid maxi prep kits were used according to manufacturer's 
instructions to prepare plasmid DNA for transfections. 200ml of LB medium 
containing the appropriate selectable marker was inoculated with an E.coli colony 
containing the plasmid of interest, and grown up overnight in an orbital shaker at 
37°C, 200rpm. Isolation of plasmid DNA was achieved by alkaline lysis of cells 
followed by purification of plasmid on the Qiagen resin, elution and precipitation 
in isopropanol. Precipitated DNA was centrifuged at 12000g for 30 minutes at 
4°C, washed in 70% ethanol, dried and re-suspended in 50pl sterile water. Details 
of this technique can be found in the Qiagen plasmid purification handbook.
DNA was quantified by spectrophotometry, reading the absorbance at 260nm and 
280nm wavelengths. DNA concentrations were determined by the 260nm reading.
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An absorbance of 1 indicated 50pg/ml of double stranded DNA. Measurement of 
absorbance at 280nm gave an estimation of the amount of protein contaminants 
present in the sample since the ratio of A260/ A280 should be 1.7 for a pure DNA 
sample. Average yields using this technique were lOOpg DNA. Plasmid stocks 
were stored at -20°C.
2.3.3 Small scale plasmid DNA extraction from E. coli
Small scale plasmid QIAprep Mini preps were used to purify DNA from several 
colonies to enable screening for the correct plasmid insert. 5ml o f LB media 
containing the appropriate selectable marker was inoculated with a single colony 
and grown overnight in an orbital shaker at 37°C, 200rpm. The culture was 
transferred to a tube and centrifuged at 5000g for 10 minute (leaving 1ml of the 
culture at 4°C for future maxiprep). Pelleted cells were re-suspended, subjected to 
alkaline lysis and neutralised. The DNA was then absorbed onto a silica gel 
membrane, washed and eluted. Details o f this technique can be found in the 
QIAprep® miniprep handbook.
2.3.4 Examination of DNA by restriction digest
Plasmid DNA was digested with restriction enzymes to characterise plasmid 
structure. 1 pg DNA was incubated with 10 units of enzyme, 1 pi enzyme buffer 
in a total volume of lOpl, made up with ddHzO at 37°C for 1 hour. The enzyme 
buffer and enzyme concentration varies for different enzymes and was carried out 
as specified by the Promega technical information sheets.
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Agarose gel electrophoresis was carried out to examine the size of the plasmid 
fragment generated by restriction digests. 1% agarose (w/v) was dissolved in 
lxTAE (0.04M Tris, 0.02M sodium acetate, ImM EDTA, adjusted to pH 8.3 with 
HC1) and melted in a microwave oven. After cooling for 5-10 minutes, ethidium 
bromide was added to a final concentration of 0.5pg/ml, and the gel was poured 
into a gel casting tray containing a suitable comb. Once set, the comb was 
removed and the gel placed in an electrophoresis tank containing lxTAE. DNA 
loading buffer 6 x stock (0.25% bromophenol blue, 0.25% xylene cyanol FF and 
30% glycerol in water) was added to DNA to a final lx  concentration. Samples 
were loaded alongside a lkb ladder and run at approximately 10 V/cm until the 
loading dye had travelled a sufficient distance through the gel. DNA bands were 
observed and photographed on a Syngene UV light box.
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2.4 Analysis of protein Levels
2.4.1 Western blotting
Cells were washed in PBS, harvested by scraping in 1 x SDS gel loading buffer 
(50mM Tris, lOOmM Dithiotheitol, 2% SDS, 0.1 % bromophenol blue, 10% 
glycerol) and heated to lOOcC for 5 minutes. Polyacrylamide gel electrophoresis 
was carried out using a 10% polyacrylamide gel (10% (v/v) acrylamide, 375mM 
Tris-HCI pH 8.8, 0.1 % (w/v) SDS, 0.05% (w/v) ammonium persulphate, 0.05% 
(w/v) N,N,N,'N'-tetramethylethylenediamine (TEMED)), with a 5% stacking gel 
(5% acrylamide, 12SmM Tris-HCI pH 6.8, 0.1 % SDS, 0.1 % ammonium 
persulphate, 0.1 % TEMED). A molecular weight rainbow marker was run to 
identify the size of protein bands. The gel was run in Tris-glycine running buffer 
(25mM Tris, 250mM glycine (pH 8.3), 0.1 % SDS) at 30mA for 4-6 hours, or 
until the dye front was within 3cm of the bottom o f the gel. Protein was 
transferred from the gel to a Hybond-c membrane overnight in a Trans-Blot 
transfer cell in blot buffer (192mM glycine 20% (w/v) methanol, 25mM Tris-HCI 
pH 8).
The membrane was then probed on a shaking platform at room temperature as 
follows: non-specific sites were blocked by incubation in block buffer (5% 
Marvel (skimmed milk powder) in PBS) for 1 hour. The primary antibody was 
then added (diluted in block buffer) and incubated over night at 4°C. The 
membrane was then 5x washed in wash buffer (1 % Marvel, 1 % Tween 20 in 
PBS) for 5 minutes. Secondary antibody (HRP conjugate, in block buffer) was
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incubated for 1 hour at RT. The membrane was then 5x washed in wash buffer for 
5 minutes per wash.
ECL was used according to manufacturer's instructions to visualise labelled bands 
by exposure to photographic film. The membrane was stripped in 0.2M  glycine 
pH 2.9 for 15 minutes and re-probed with an antibody to actin to check for equal 
protein loading. Bands were quantified by densitometry on a BioRad GS-800 
densitometer. Antibodies and conditions for use are shown in Table 2.2.
Primary antibody Dilution Secondary antibody Dilution
CBP (C-l) monoclonal 1:50 Anti-Mouse Ig HRP 1:1000
PS1 polyclonal 1:1000 Anti-Rabbit Ig HRP 1:1000
Actin (1-19) monoclonal 1:2000 Anti-Goat Ig HRP 1:2000
Histone H4 polyclonal 1:1000 Anti-Rabbit Ig HRP 1:1000
Acetyl-Histone H4 polyclonal 1:1000 Anti-Rabbit Ig HRP 1:1000
GAL4 (DNA binding domain) 1:200 Anti-Rabbit Ig HRP 1:1000
Table 2.2 Antibody Conditions for western blots and immunofluorescence.
2.4.2 Confocal immunofluorescence
Cells were washed in PBS and were fixed in by adding -20°C methanol on ice for 
10 minutes. Cells were then washed in PBS, and incubated in PBS 3% BSA for
87
blocking (3% BSA, 0.05% sodium azide in PBS) to block non-specific sites of 
antibody adsorption. Samples were stored at 4°C.
Primary CBP antibody was added to each sample for over night at 4°C, washed in 
PBS and non-specific sites blocked in block buffer for 15 minutes at room 
temperature. Secondary anti-mouse IgGl: RPE and DAPI stain (0.5 jig/ml) were 
added for 1 hour at room temperature (kept in the dark). Cells were washed in 
PBS and analyzed using Leica TCS SPE confocal microscop, which is capable of 
producing large xy and z montages.
2.4.3 Protein Assay 
The amount of protein in the samples was quantified using the bicinchoninic 
(BCA) Protein Assay Reagent kit according to the manufacturer's instructions. 
This method uses colorimetric detection combining the reduction of Cu2+ to Cu1+ 
by protein in an alkaline medium with the highly sensitive colorimetric detection 
of cuprous cation using a reagent containing BCA. Diluted bovine serum albumin 
(BSA) standards were prepared and the cell lysate diluted using lOpl cell lysate 
and 40pl ddHzO. 50pl standards and diluted cell lysates ,were added to a 96 well 
microplate, 200pl BCA working reagent added to each well and the plate 
incubated at 37°C for 1 hour. The absorbance was measured at 560nm on a plate 
reader and the protein concentration calculated from the standard curve.
2.5 Assessment of promoter activity
lOOpl o f lx  reporter lysis buffer was added to each well o f cultured cells (based 
on 6 well plate) cells scraped with a rubber policeman and transferred to sterile 
1.5ml microcentrifuge tubes. Samples centrifuged at 12000g for 1 minute to pellet 
cellular debris and the supernatant was transferred to sterile 1.5ml microcentrifuge 
tubes. Cell extracts were used to measure reporter construct activity.
2.5.1 Luciferase assay 
The amount o f luciferase produced by luciferase reporter constructs was 
quantified using a Luciferase Reporter 1000 assay system, according to the 
manufacturer's instructions. 50pl o f cell extract was mixed with lOOpl luciferase 
reagent and read for 20 seconds in a luminometer after a 5 second delay. This 
value represents the amount of firefly luciferase present in the sample. 
Transfections were equalised by measuring Renilla luciferase activity using the 
same procedure and this value was subsequently used to normalise values 
obtained in the firefly assay.
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2.6 Animals
Hemizygous transgenic (HuAPP695SWE)2576 mice expressing mutant human 
APP (K670N,M671L)(Hsiao et al., 1996) were crossed with hemizygous PS1 
mice that express mutant human PS1 (Ml46V; line 6.2)(Duff et al., 1996). The 
offspring, double-transgenic mice overexpressing APP/PS1, were compared with 
their WT littermates so that age and background strain were comparable. To 
identify the genotype of the animals, we used DNA extracted from tail tissue(Duff 
et al., 1996; Hsiao et al., 1996).
2.6.1 Drug administration.
Three-month-old APP/PS1 and WT mice were evenly separated into 4 groups: 
APP/PS1 mice treated with vehicle, APP/PS1 mice treated with TSA, WT mice 
treated with vehicle, and WT mice treated with TSA. For assessment of the short­
term effects of TSA, the drug was given at a concentration of 2pgr per gram of 
body weight via i.p. injection 2 hours minutes before the behavioral tests. Finally, 
the animals were sacrificed for western blot analysis.
2.6.2 Measurement of LTP
Mice were decapitated, and their hippocampi were removed. Transverse 
hippocampal slices of a thickness of 400 pm were made on a tissue chopper and 
transferred to an interface chamber, where they were maintained at 29°C. They 
were perfused (1-3 ml/min) with saline solution (124.0 mM NaC 1/4.4 mM 
KC1/1.0 mM Na2HPO4/25.0 mM NaHCO3/2.0 CaCL2/2.0 mM MgSO4/10 mM 
glucose) continuously bubbled with 95% 02  and 5% C02. Slices were permitted
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to recover for at least 90 min before recording. A concentric bipolar platinum- 
iridium stimulation electrode and a low-resistance glass recording microelectrode 
filled with saline solution (5 mQ resistance) were placed in CA1 stratum radiatum 
to record the extracellular field excitatory postsynaptic potential (fEPSP). An 
input-output curve was used to set the baseline fEPSP at -35%  of maximal slope. 
Baseline stimulation was delivered every minute (0.01-ms duration pulses) for 15 
min before beginning the experiment to assure stability of the response. TSA 
(1.65 pM) or vehicle was added (in 0.1% DMSO) to perfused slices for 30 min in 
interleaved experiments. LTP was induced by using 0-burst stimulation (4 pulses 
at 100 Hz, with the bursts repeated at 5 Hz and each tetanus including three 10- 
burst trains separated by 15 s). Responses were recorded for 1 h after tetanization.
2.6.3 Contextual fear conditioning
Our conditioning chamber was located inside a sound-attenuating box (72 cm x 
51 cm x 48 cm). A clear Plexiglas window (2 cm x 12 cm x 20 cm) allowed the 
experimenter to film the mouse performance with a camera placed on a tripod and 
connected to Freezeframe software (MED Associates Inc.). To provide 
background white noise (72 dB), a single computer fan was installed in 1 of the 
sides of the sound-attenuating chamber. The conditioning chamber (33 cm x 20 
cm x 22 cm) was made of transparent Plexiglas on 2 sides and metal on the other 
2. One o f the metal sides had a speaker and the other had a 24-V light. The 
chamber had a 36-bar insulated shock grid floor. The floor was removable and 
after each use we cleaned it with 75% ethanol and then with water. Only 1 animal 
at a time was present in the experimentation room. The other mice remained in 
their home cages.
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During the contextual conditioning experiment, mice were placed in the 
conditioning chamber for 2 minutes. In the last 2 seconds of the 2 minutes, mice 
were given a foot shock (US) of 0.50 mA for 2 seconds through the bars of the 
floor. After the US, the mice were left in the conditioning chamber for another 30 
seconds and then were placed back in their home cages. “Freezing” behavior, 
defined as the absence of all movement except for that necessitated by breathing, 
was assigned scores using Freezeview software (MED Associates Inc.). For 
evaluation of contextual fear learning, freezing was measured for 5 (consecutive) 
minutes in the chamber in which the mice were trained at 24 hours after training.
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2.7 Statistical Analysis
Where only two comparisons were required in a data set, student's t-tests were 
used to test for a significant difference between means, with a P value of less than 
0.05 taken as significant. Two sample t-tests assuming unequal variance were 
performed using SPSS.
Where multiple comparisons were required between treatment groups, single 
factor analysis of variance (ANOVA) was used to look for differences between 
treatments. Single factor ANOVA was carried out using SPSS and a P value of 
less than 0.05 was taken as significant, t-tests are not recommended for multiple 
comparisons as the risk of obtaining a type I error (i.e. a false positive) is 
increased as more tests are performed. The Bonferroni test is a modified t-test 
where the P value is multiplied by the number of tests performed on the same 
data. This makes the chance o f achieving significance less likely, and thus reduces 
the chance of type I errors. When ANOVA showed significant differences 
between groups, the Bonferroni method was performed post-hoc to test for 
significant difference between specific treatments. For LTP experiments the data 
analysis was performed with a factorial ANOVA with post hoc correction. The 
results were expressed as mean ± SEM. Significance was determined at the level 
of P less than 0.05.
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Chapter 3
3 THE EFFECTS OF PS1 ON CBP
3.1 Introduction
As mentioned in section 1.8, AD is an age-related neurodegenerative disorder that 
is associated with the deterioration of memory and a progressive cognitive decline 
with the formation of neurofibrillary tangles and amyloid plaques. Three AD 
associated genes, APP, PS1 and PS2, were found to be the primary cause of the 
FAD(Kang et al., 1987; Levy-Lahad et al., 1995; Sherrington et al., 1995). PS1 is 
a part of the y-secretase complex which is responsible for the cleaving of APP, 
leading to the increased production of Ap42 peptide suggesting a toxic gain-of- 
function pathogenic mechanism.
As described in section 1.6, intensive studies o f the mechanisms underlying 
memory formation have defined central roles for CRE-dependent gene 
expression, which is mediated by the transcription factor CREB and its 
coactivator CBP. CBP was found to acetylate histones and to form a bridge 
between the CREB-CBP complex and the basal transcriptional machinery 
resulting in transcriptional activity (Victor et al., 2002).
Previous investigations, as described in section 1.9, of normal presenilin function 
revealed a contradictory role of PS 1-CBP in neurodegeneration. Thus, PS 1 and 2 
conditional double knockout mice showed reductions in CBP levels and in CRE- 
dependent gene expression in the cerebral cortex, which is likely to contribute to 
subsequent neuronal degeneration(Saura et al., 2004) 17. In contrast, it has been 
shown that wild type PS1 cleaves the transmembrane protein N-cadherin to 
release an intracellular fragment. In turn, this fragment has been shown to bind to
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CBP and promote rapid proteasomal degradation(Marambaud et al., 2003). 
Moreover, it has been shown that the mutant forms of PS1 found in familial 
Alzheimer's disease (FAD) cannot cleave N-cadherin and therefore do not 
promote the degradation of CBP. This suggests that, in contradiction to Saura et 
al, the mutation in PS1 would result in enhanced levels of CBP and that CBP 
over-expression is toxic in certain conditions.
In view of this contradictory literature, we began to investigate the potential role 
of CBP in Alzheimer's disease by studying its activity and the effects of 
manipulating its expression in cells containing wild type or mutant forms of the 
proteins that are mutated in the familial forms o f Alzheimer's disease (FAD). To 
investigate the role of CBP we used a neural cell line (F ll) , which allows the 
inducible over-expression of wild type or mutated PSl(Hashimoto et al., 2002). In 
addition, in order to measure CBP activity, we used plasmid constructs in which 
CBP is linked to the DNA-binding domain of the yeast Gal-4 transcription factor 
and which therefore allows constitutive recruitment of CBP to the DNA so that its 
ability to stimulate transcription can be directly measured (Fig 3.1). We have 
previously used this system to demonstrate, for example, that NGF stimulates 
CBP activity in neuronal cells(Liu et al., 1998).
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Figure 3.1 CBP/Gal4 Chimera
CBP/Gal4 hybrid and a reporter plasmid in which luciferase expression is driven by a 
Gal4 yeast promoter.
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3.2 The effect of WT/mutant PS1 on the transcriptional activity of CBP
The Gal-CBP construct was therefore transfected into the F ll/E cR  line together 
with the reporter luciferase construct, and the cells were either left untreated or 
transfected with wild type PS1 or mutated M146L PS1 and EcD was used to 
induce PS1 expression. As mentioned in section 2.2, F l l  are one of the best 
models for primary cultured neurons; they exhibit, without differentiation factor 
treatment, a number of characteristics of primary neurons, including generation of 
action potentials, synthesis of neurotransmitters, expression of neuropeptide 
receptors, and voltage-gated calcium channels(Hashimoto et al., 2002; Jow et al., 
2006).
In these experiments, a significant enhancement of CBP driven promoter activity 
was observed in the cells transfected with constructs containing wild type PS1 
(Fig. 3.2). Compared to the control, wild type PS1 produced no enhanced activity 
when a construct containing the isolated DNA binding domain of Gal 4 without 
CBP was transfected (Fig. 3.3), indicating that wild type PS1 enhances the 
transcriptional stimulating ability of CBP. Remarkably, the mutant form of PS1 
produced virtually no enhancement in promoter activity, showing similar activity 
levels to the untreated cells (Fig. 3.2). These results demonstrate that the mutant 
form o f PS1, unlike wild type PS1, has no ability to activate CBP (Fig, 3.2). In 
addition, virtually no enhancement in CBP activity was observed, in the absence 
o f PS1 transfection, when cells were treated with EcD, showing that EcD itself 
has no effect on CBP activity (Fig. 3.4). These experiments were routinely done 
with the addition of EcD to induce PS1 expression. Only minor enhancement in
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CBP activity was observed, in the absence of EcD, when the cells were 
transfected with WT PS1 (Fig. 3.4).
As mentioned in section 1.8, there are 147 different PS1 mutants. It was therefore 
decided to examine if other PS1 mutations would lead to a reduction in CBP 
activity as demonstrated in the case of PS1 M146L mutant. Moreover, it was 
decided not to conduct this experiment in the EcD inducible system and to use a 
pcDNA3 expression vector in order to avoid any effect EcD might have on CBP 
activity and to show the general effect of PS1 mutants.
The Gal-CBP construct was therefore transfected into the F ll/E cR  line together 
with the reporter luciferase construct, and the cells were either transfected with 
empty pcDNA3 vector (control)/pcDNA3 wild type PS1 or PS1 mutants (Y115H, 
M146L, E318G and L392V all in pcDNA3 vector). As in the experiments above, 
a significant enhancement of CBP driven promoter activity was observed in the 
cells transfected with the construct containing wild type PS1 (Fig. 3.5). 
Interestingly, PS1 N-terminal mutants (Y115H and M146L) produced no 
enhanced activity and showed similar activity levels to the control cells (Fig. 3.5). 
Moreover, PS1 C-terminal mutants (E318G and L392V) showed a reduction in 
promoter activity compared to the pcDNA3 vector control. These results 
demonstrate that not only do PS1 mutants, unlike wild type PS1, have no ability 
to stimulate CBP transcriptional activation but that C-terminal PS1 mutants 
actually reduce CBP activity (Fig. 3.5).
The increase o f CBP driven promoter could be as a result of increase of CBP
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levels, increase in CBP enzymatic activity or even both. It was therefore decided 
to examine if transfected Gal-CBP levels change during the Gal-CBP 
experiments. Western blots analysis of extracts prepared from F l l  cells 
transfected with Gal-CBP construct together with empty pcDNA3 vector 
(control)/pcDNA3 WT PS1 or pcDNA PS1-M146L, using Gal4 DNA binding 
domain antibody, showed no difference in levels of Gal-CBP between the three 
different groups (Fig 3.6).
Additionally, it was decided to measure endogenous CBP levels in order to 
determine if, in addition to CBP changes in enzymatic activity, a decrease in CBP 
levels is involved in the observed reduction in CBP driven promoter activity when 
PS1-M146L mutant is transfected. Western blot analysis of extracts prepared from 
F ll  cells transfected with pcDNA3 WT PS1 revealed, compared to control, a 
significant increase in levels of endogenous CBP (Fig 3.7). In addition, an 
increase in CBP endogenous levels was noted when the cells were transfected 
with pcDNA3 PS1-M146L, however, these levels were still significantly lower 
when compared to cells transfected with pcDNA3 WT-PS1 (Fig 3.7).
Therefore, while wild type PS1 increases endogenous CBP levels more than PS1- 
M146L mutant, it does not account for our Ga4-CBP results. Gal4-CBP activity 
changes cannot be explained by changes in Gal4-CBP level since Gal4-CBP 
levels stay the same during the luciferase experiments. Consequently effects on 
Gal4 promoter must be due to changes in the activity of CBP, enhancing its ability 
to activate transcription.
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Figure 3.2 Effect of wild type or m utated  PS1 on the transcrip tional activity 
of CBP in F l l  cells.
Luciferase assay results o f  co-transfecting F l l  cells with 2 gg o f  the Gal4-E1B 
TATA-luciferase, 2 gg o f  the Gal-CBP (full length)-in the presence or absence o f 
with wild type or mutated PS1 (1 gg). Values are expressed relative to the level o f 
luciferase in control, neural cells transfected with Gal-luciferase and Gal-CBP (set 
at 100%) and are the means o f  three independent transfection experiments whose 
standard error is indicated by the bars. *, p < 0.05 versus control.
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Figure 3.3 Effect of wild type PS1 on the transcriptional activity of Gal-4 in 
F l l  cells.
Luciferase assay results o f  co-transfecting F l l  cells with 2 gg o f the Gal4-E1B 
TATA-luciferase, 2 gg o f the Gal-4 in the presence or absence o f with wild type 
PS1 (1 gg). Values are expressed relative to  the level o f  luciferase in control, 
neural cells transfected with Gal-luciferase and Gal-4 (set at 100%) and are the 
means o f  three independent transfection experiments whose standard error is 
indicated by the bars. * , P <  0.05 versus control.
102
400h
300-
20Q-
J 100-
§
9
o
Gal-CBP full length
I
*
Figure 3.4 Effect o f EcD and wild type PS1 on the transcriptional activity of 
CBP in F l l  cells.
Luciferase assay results o f  co-transfecting F l l  cells with 2 gg o f the Gal4-E1B 
TATA-luciferase, 2 gg o f  the Gal-CBP (full length)-in the presence or absence o f 
with wild type PS1 (1 gg) -in the presence or absence o f  EcD (40 gM). Values are 
expressed relative to the level o f  luciferase in control, neural cells transfected with 
Gal-luciferase and Gal-CBP (set at 100%) and are the means o f  three independent 
transfection experiments whose standard error is indicated by the bars. *, p < 0.05 
versus control.
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Figure 3.5 Effect of wild type or different mutations of PS1 on the 
transcriptional activity of CBP in F l l  cells.
Luciferase assay results o f  co-transfecting F l l  cells with 2 gg o f the Gal4-E1B 
TATA-luciferase, 2 gg o f  the Gal-CBP (full length)-in the presence or absence of 
with PS1 wild type or one o f  PS1 mutants (Y115H, M146L, E318G and L392V) 
(1 gg). Values are expressed relative to the level o f  luciferase in control, neural 
cells transfected with Gal-luciferase and Gal-CBP (set at 100%) and are the 
means o f  three independent transfection experiments whose standard error is 
indicated by the bars. *, p <  0.05 versus control.
104
(A 130-  
120-
3  1 1 ° "
g 100-
I  9CH 
80
Gal4
Aclin
Figure 3.6 Effect of PS1 WT/mutant on transfected CBP levels
Expression o f  Gal4 in FI 1. Cells were transfected with Gal-CBP together with an 
empty pcDNA3 vector/pcDNA3 WT PSl/pcDNA3 PS1-M146L. Values are 
means o f  three independent transfection experiments whose standard error is 
indicated by the bars, p >0.05 versus control. Results were normalized against the 
control. *, p < 0.05 versus control
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Figure 3.7 Effect of PS1 WT/mutant on endogenous CBP levels
Endogenous expression o f  CBP in F l l  cells that were transfected either with an 
empty vector or PS1 WT/M146L in a pcDNA3 vector. Values are means o f three 
independent transfection experiments whose standard error is indicated by the 
bars, p >0.05 versus control. Results were normalized against the control. *, p < 
0.05 versus control
3.3 Localisation of CBP during WT PS1 upregulation
To confirm our experiments with the WT and mutant PS1, we used confocal 
immunofluorescence analysis, as in our similar studies on the localisation of the 
Parkinson's disease-associated protein, Parkin(Muqit et al., 2004), to investigate 
the effect o f both mutant and wild type PS1 over-expression on the location of 
CBP in the cell. We showed that CBP, in the absence of either WT or Mutant 
PS1, can be detected in both cytoplasmic and nuclear compartments (Fig. 3.8). In 
those cells which over-express wild type PS1, CBP is found mostly in the nucleus 
(Fig. 3.8). In contrast, in those cells that over-express the mutant form of PS1, 
CBP is seen in both the cytoplasm and the nucleus. Taken together, our findings 
clearly show that CBP, which in its active form is found in the nucleus (Chrivia et 
al., 1993), is activated by the wild type PS1 and not by mutant PS1.
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Figure 3.8 Effect o f wild type and mutated PS1 on the cellular localizatio 
CBP in F l l  cells.
Immunofluorescence results o f  F l l  cells transfected with 1 pg o f  RSV-CBP (full 
length)-in the presence o f  wild type or mutated PS1 or pcDNA(l pg). Cells v —
plated onto coverslips, fixed and prepared for indirect im m unofluorescence.___
CBP protein was detected using the mouse monoclonal anti-CBP antibody (shown 
in green). Cells were counterstained with the Hoechst DNA dye (shown in blue). 
Both CBP and Hoechst staining patterns were merged. Digital images \  
captured using a Zeiss Axiocam camera. Representative fields are displayed. A) 
In control cells transfected with CBP and pcDNA, CBP was detected in the 
cytoplasm and the nucleus. B) In cells transfected with CBP and WT PS1, CBP 
was detected predominantly in the nucleus. C) In cells transfected with CBP and 
APS1, CBP was detected both in the nucleus and cytoplasm.
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3.4 Signalling pathways involved in the upregulation of CBP activity by 
PS1
To investigate the mechanisms mediating the effect of WT PS1, the experiments 
were repeated in the presence or absence of the inhibitors LY 294002, SB 203580 
and PD 98059 which specifically inhibit the activity of PI 3-kinase, p38 MAP 
kinase and p42/p44 MAP kinase pathways respectively(Alessi et al., 1995; Vlahos 
et al., 1994; Young et al., 1997). In these experiments addition of PD resulted in a 
slight increase in the basal activity produced by the CBP in the absence of WT 
PS1 (Fig. 3.9A) whereas the addition of LY and SB did not show such an effect. 
In addition, the up-regulation of CBP activity by WT PS1 was prevented by 
addition o f LY, SB and PD (Fig. 3.9B), resulting in a similar lack of CBP activity 
to that produced by the mutant form of PS1. In addition, CBP showed the same 
activity in the presence of the mutant form of PS1, with or without the inhibitors 
LY 294002, SB 203580 and PD 98059 (Fig. 3.10). This suggests therefore that in 
neuronal cells the ability of WT PS1 to stimulate the transcriptional activity of 
CBP involves the PI 3-kinase, p38 MAP kinase and p42/p44 MAPK pathways.
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Figure 3.9 Effect of specific inhibitors on the up-regulation of CBP activity 
by W T PS1 in F l l  cells.
Luciferase assay results o f co-transfecting F l l  cells with 2 pg of the Gal4-E1B 
TATA-luciferase, 2 pg o f  the Gal-CBP (full length) construct. The MAPK 
inhibitors SB (10 pM), PD (25 pM) and LY (50 pM) were added 24 hr after the 
transfection with (B) or without (A) the presence o f WT PS1 (1 pg). Values are 
expressed relative to the level o f  luciferase in control, untreated transfected F l l  
cells (set at 100%) and are the means o f  three independent transfection 
experiments whose standard error is indicated by the bars. *, p < 0.05 versus 
control.
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Figure 3.10 Effect of specific inhibitors on the regulation of CBP activity by 
mutant form o f PS1 in F l l  cells.
Luciferase assay results o f  co-transfecting F l l  cells with 2 pg o f the Gal4-E1B 
TATA-luciferase, 2 pg o f  the Gal-CBP (full length) construct. The MAPK 
inhibitors SB (10 pM), PD (25 pM) and LY (50 pM) were added 24 hr after the 
transfection with the presence o f  mutant form o f PS1 (1 pg). Values are expressed 
relative to the level o f  luciferase in control, untreated transfected FI 1 cells (set at 
100%) and are the means o f  three independent transfection experiments whose 
standard error is indicated by the bars. *, p < 0.05 versus control.
I l l
3.5 Regions of CBP involved in activation by WT PS1
In our previous experiments(Liu et al., 1998) we demonstrated that the ability of 
NGF to stimulate the transcription activating ability of CBP was also dependent 
on the p42/p44 MAPK pathway and was observed with constructs containing two 
small independent regions at the C terminus of CBP. To determine whether a 
similar effect could be observed in the case of wild type PS1, we transfected a 
wide variety o f constructs containing different N-terminal and C-terminal regions 
o f CBP linked to the Gal 4 DNA binding domain and analyzed their response to 
wild type PS1. In these experiments (Fig. 3.11) a strong response to wild type PS1 
was observed with the construct containing the C-terminal region of CBP from 
amino acids 2173 through 2288. In addition, smaller responses o f approximately 
1.5-fold were observed with N-terminal regions 1-460, 721- 1679 and 1678-1843 
(Fig. 3.11). However, a decreased activity in response to WT PS1 was shown with 
the construct containing the region of CBP from amino acids 1961-2039 (Fig. 
3.11). This suggests that multiple regions at the N terminus of CBP can mediate 
the response to wild type PS1, but that a single short C terminus region produces 
the strongest effect.
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Figure 3.11. Effect of wild type PS1 on the transcriptional activity of 
different N-terminal and C-terminal regions of CBP in neural cell.
Luciferase assay results o f  co-transfecting F l l  cells with with 2 pg o f the Gal4- 
E1B TATA-luciferase together with 2 pg o f the CBP C-terminal regions (amino 
acids 1961-2039, 2060-2179, 2173-2288, or 2288-2441) or CBP N-terminal 
regions (amino acids 1-460, 721-1679, 1678-1843 or 1844-1956) linked to Gal4 
in the presence o f  WT PS1 (1 pg). In each case values are expressed relative to 
the level o f luciferase in untreated FI 1 cells transfected with each construct (set at 
100%) and are the means o f  three independent transfection experiments whose 
standard error is indicated by the bars. *, P < 0 .05 versus the same construct 
without WT PS1.
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To determine whether a similar effect could be observed in the case of presenilin 
1 M146L mutant form, we transfected a wide variety of constructs containing 
different N-terminal and C-terminal regions of CBP linked to the Gal4 DNA 
binding domain into the FI 1/EcR line and analyzed their response to Presenilin 1 
M146L mutant form. Cells were either left untreated or transfected with wild-type 
or mutated presenilin 1 and EcD used to induce PS1 expression. In these 
experiments, as in our previous one, WT PS1 was able to stimulate both the C and 
N-terminal regions of CBP. However, the presenilin 1 M146L mutant form 
produced virtually no enhancement in promoter activity, showing similar activity 
levels to the untreated cells. These results demonstrate that the presenilin 1 
M146L mutant form, unlike wild-type Presenilin 1, has no ability to activate 
different regions of CBP (Fig. 3.12).
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Figure 3.12 Effect of wild type and mutant forms of Presenilin 1 on the 
transcriptional activity of different N-terminal and C-terminal regions of 
CBP in neural cells.
Luciferase assay results o f  co-transfecting F l l  cells with 2 pg o f the Gal4-E1B 
TATA-luciferase together with 2 pg o f  the CBP C-terminal region (amino acids 
2173-2288) or CBP N-terminal regions (amino acids 1-460, 721-1679, 1678- 
1843) linked to Gal4 in the presence o f  wild-type or mutant presenilin 1 (1 pg). 
Values are expressed relative to  the level o f  luciferase in control (neural cells 
transfected with Gal-luciferase, different regions o f  Gal-CBP and 1 pg o f  empty 
vector) set at 100%. Values are the means o f  3 independent transfection 
experiments whose s.e. is indicated by the bars. * p<0.05 vs control.
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3.6 PS1 endogenous knockdown effect on the transcription activity of 
CBP
To determine the molecular mechanism underlying the observed reduction in CBP 
driven promoter activity in PS1 mutants, we decided to measure CBP driven 
promoter activity when endogenous PS1 is knocked down by using PS1 siRNA. 
Evidence showing that PS1 siRNA eliminates PS1 endogenous expression was 
provided by using western blot analysis. F l l  cells were transfected with PS1 
siRNA and as a non-specific control we used siGENOME Non-Targeting siRNA 
#1, which does not target luciferase, Gal4 DNA binding domain and renilla 
(Sullivan et al., 2007). The result of this experiment showed a dramatic decrease 
in levels o f endogenous PS1 (Fig 3.13), confirming that the cells transfected with 
PS1 siRNA showed reduced PS1 expression. Moreover, we also confirmed the in 
vivo results of Saura et al., which showed a decrease in CBP levels in PS cDKO 
mice (Saura et al., 2004). We were able to show that endogenous knockdown of 
PS1 leads to a decrease in endogenous CBP levels in vitro (Fig 3.13).
We then wanted to see if, in addition to a decrease in endogenous CBP, CBP 
enzymatic activity is also affected by the knockdown of PS1. The Gal-CBP 
construct was therefore transfected into the F ll/E cR  line together with the 
reporter luciferase construct, and the cells were either transfected with lpg of 
siGENOME Non-Targeting siRNA #1 or PS1 siRNA. Compared to the control, 
PS1 siRNA transfected cells showed a decreased promoter activity, indicating that 
the knockdown of PS1 decreases the transcriptional stimulating ability of CBP 
(Fig 3.14). As mentioned in section 3.2, the decrease o f CBP driven promoter 
could be as a result of decrease of CBP levels and/or decrease in CBP enzymatic
activity. It was therefore decided to examine if the decrease in CBP promoter 
activity is due to a decrease in CBP levels and/or a decrease in CBP enzymatic 
activity. Western blots Analysis of extracts prepared from F l l  cells transfected 
with siRNA and Gal-CBP, using Gal4 DNA binding domain antibody, showed no 
significant difference in levels of Gal-CBP (Fig 3.15), suggesting that PS1 
knockdown affects both CBP levels and CBP enzymatic activity.
Therefore, while PS1 knock down decreased endogenous CBP levels, it does not 
account for our Ga4-CBP results. Gal4-CBP activity changes cannot be explained 
by changes in Gal4-CBP level since Gal4-CBP levels stay the same during the 
luciferase experiments. Consequently effects on Gal4 promoter most be due to 
changes in activity o f CBP, enhancing its ability to activate transcription.
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Figure 3.13 Effect of PS1 siRNA on endogenous PS1 and CBP levels
Endogenous expression o f PS1 and CBP in F l l  cells that were transfected either 
with siGENOME Non-Targeting siRNA #1 (1 jj.gr) or siRNA. Values are means o f 
three independent transfection experiments whose standard error is indicated by 
the bars, p >0.05 versus control. Results were normalized against the control. *, p 
< 0.05 versus control
118
ar
8 isch _
Gal-CBP full length
I  10Ch
50-
Control PS1 siRNA
Figure 3.14 Effect of PS1 endogenous knockdown on the transcriptional 
activity of CBP in F l l  cells.
Luciferase assay results o f  co-transfecting F l l  cells with 2 pg o f the Gal4-E1B 
TATA-luciferase, 2 pg o f  the Gal-CBP (lull length)- with siGENOME Non- 
Targeting siRNA #1 (lp g r) or o f  PS1 siRNA (1 pgr). Values are expressed 
relative to  the level o f  luciferase in control, neural cells transfected with Gal- 
luciferase and Gal-CBP (set at 100%) and are the means o f  three independent 
transfection experiments whose standard error is indicated by the bars. *, p < 0.05 
versus control.
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Figure 3.15 Effect of PS1 endogenous knockdown on transfected CBP levels
Expression o f  Gal4 in F l l .  cells that were transfected either with siGENOME 
Non-Targeting siRNA #1 (ljig r) or PS1 siRNA.Values are means o f three 
independent transfection experiments whose standard error is indicated by the 
bars, p >0.05 versus control. Results were normalized against the control. *, p < 
0.05 versus control
3.7 Discussion
Subsequent to the first identification of CBP, a number of studies have explored 
its functional properties and CBP is now known to be a co-activator for a number 
o f transcription factors (see section 1.5). CRE-dependent gene expression has 
been shown to play a role in the consolidation of long-term forms of synaptic 
plasticity and memory(Silva et al., 1998). In the case of PS1, initial studies 
demonstrated that loss o f presenilins causes reduced expression of CBP and 
CREB/CBP target genes(Saura et al., 2004). Moreover, since CBP is an essential 
cofactor for transcriptional activation by CREB, diminished CBP expression 
represents the likely basis for the global reduction in the transcription of CRE- 
bearing genes which play an important role in neuronal survival(Walton and 
Dragunow, 2000). However, regulation of CBP activity in response to WT PS1 
and mutant PS1 has not previously been reported.
Although initially linked with APP and Notch processing, it is apparent that PS-1 
is involved in the proteolytic processing of a range of additional transmembrane 
proteins, including N-cadherin(Marambaud et al., 2003), which are known to 
modulate various aspects of neuronal development and function(Hjorth et al., 
2001; Kiryushko et al., 2004). Moreover, PS1 M146L mutant was shown to cause 
neuronal cell death through to sensitivity to apoptosis(Hashimoto et al., 2002).
The data presented here add a new aspect to this by indicating that WT PS1, but 
not the mutant PS1 M146L form, can stimulate the transcriptional activation 
ability of CBP and increase CBP levels. To date, there are 170 known mutations 
in PS1, divided into N-terminal and C-terminal mutations, that are known to lead
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to a familial form of Alzheimer’s disease (Alzheimer Disease & Frontotemporal 
Dementia Mutation Database). As discussed in section 1.8, PS1 mutations are 
known to lead to enhance deposition of A(342 senile plaques in the brain(Gomez- 
Isla et al., 1999). However, not all PS1 mutations lead to neuronal loss in a similar 
way. Hashimoto et al. examined 27 different FAD linked mutants of PS1, and 
found that N- and C-terminal PS1 mutants can generate distinct neurotoxic 
signals(Hashimoto et al., 2004). Thus, the PS1 mutants whose mutations are 
located in the N-terminal, cause NOS inhibitor-sensitive neurotoxicity. On the 
other hand, the PS 1 mutants whose mutations are located in the C-terminal, cause 
NADPH oxidase inhibitor-sensitive neurotoxicity. This suggests that different 
mutations in PS1 might lead to neuronal cell death through different toxic 
mechanisms. We were able to show that unlike wild type PS1 both N and C- 
terminus mutations of PS1 were not able to stimulate the transcriptional activation 
ability of CBP. Moreover, PS1 C-terminus mutations showed a decrease in CBP 
transcriptional activity compared to control vector or PS1 N-terminus mutations.
Evidently, all our experiments investigating the effect of PS1 on CBP use 
Gal4/CBP fusion proteins, and this approach has been criticized, because of the 
artificial nature o f the constructs used(Cardinaux et al., 2000). Here, the results 
have been independently confirmed using confocal immunofluorescence, which 
showed the different effect of wild type and mutated PS1 on the cellular 
localization o f CBP. These findings clearly show that CBP, which in its active 
form is found in the nucleus, is activated by the wild type PS1 and not by mutant 
PS1.
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A variety of recent data suggests that CBP is a target for specific signalling 
pathways. Interestingly, the C terminus of CBP, which mediates the strongest 
response to WT PS1, was also identified to be involved in its response to 
phenylephrine(Gusterson et al., 2002). Moreover, previous work has 
demonstrated that NGF was able to enhance CBP-Gal 4 activity via the p42/p44 
MAPK pathway(Liu et al., 1998). The work presented here extends these studies 
to show wild type PS1 activates CBP and that this activity is dependent upon its 
ability to activate the PI 3-kinase, p38 MAP kinase and p42/p44 MAPK 
pathways. In addition, the data presented here suggests that different regions of 
CBP, primarily the C terminus, are activated by WT-PS1, but not by its mutant. 
This is of interest since recent studies have revealed that the C-terminal activation 
domain of CBP interacts with components of the basal transcriptional machinery 
such as TFIIB72 and the RNA polymerase holoenzyme complex as well as the 
transcriptional co-activator p/CIP(Kee et al., 1996; Torchia et al., 1997). 
Moreover, the increased activity of the CBP region containing amino acids 721- 
1679 induced by wild type PS1 was of particular interest since it contains the CBP 
acetyltransferase domain(Martinez-Balbas et al., 1998).
As mentioned in section 1.9, Saura et al have shown a reduction in CBP levels 
and CRE-dependent gene expression in their PS cDKO (Saura et al., 2004). 
However, they did not show if the reduction of CRE-dependent gene expression is 
a result o f a decrease in CBP activity as well as a decrease in CBP levels. Here we 
used an in vitro approach to confirm the results of Saura et al by showing a 
decrease in CBP levels when endogenous PS1 was knocked down. Moreover, we 
were able to show, by using luciferase assay and Gal4 western blot, that when
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PS1 is knocked down there is a decrease in CBP levels and there is a decrease in 
the transcriptional activation ability of CBP.
Importantly, in all of the experiments above we were able to show that the Gal- 
CBP luciferase results are not explained by changes in Gal4-CBP levels. Here the 
effects on the Gal4 promoter are due to by changes in CBP activity, enhancing its 
ability to activate transcription.
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Chapter 4
4 THE EFFECTS OF PS1 ON P300
4.1 Introduction
As mentioned in section 1.8, it has been shown that CBP, but not p300, is 
involved in AD development (Teo et al., 2005). This result is perplexing since, as 
mention in section 1.6, CBP and p300 have a high degree of homology and similar 
patterns of expression. Moreover, p300 and CBP were shown to response 
similarly, but not identically, to different cell stimuli. Thus, we would expect that 
p300 would show similar level o f involvement in AD as CBP showed in the last 
chapter. We therefore decided to examine the potential part of p300 in AD. In this 
chapter, the role of p300 in AD is tested by studying p300 activity and the effects 
of manipulating its expression in cells containing wild type or mutant forms of the 
proteins that are mutated in the FAD.
4.2 The effect of WT/mutant PS1 on the transcriptional activity of p300
To investigate the potential role of p300 in Alzheimer's disease we co-transfected 
Gal-p300 constructs with a plasmid containing a test promoter with DNA binding 
sites for Gal4 linked to the luciferase reporter gene. This allows the effect o f any 
stimulus on the ability of p300 to activate transcription to be assessed without any 
complications arising from it being recruited to the DNA via interaction with a 
DNA-bound transcription factor that may itself be modulated by the stimulus. We 
have previously used this system to demonstrate that NGF stimulates p300 
activity in neuronal cells(Liu et al., 1998) and to demonstrate the effect of PS1 on 
CBP transcriptional activity in the previous chapter .
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The Gal-p300 construct was therefore transfected into FI 1/EcR line together with 
the reporter luciferase construct, and the cells were either left untreated or 
transfected with wild type or mutated PS land EcD used to induce PS 1 expression. 
In these experiments, a significant enhancement of p300 driven promoter activity 
was observed in the cells transfected with constructs containing wild type 
Presenilin 1, compared to control where Gal-p300 was transfected with an empty 
vector (Fig 4.1). Remarkably, the PS1M146L mutant form produced virtually no 
enhancement in promoter activity, showing similar activity levels to the untreated 
cells. These results demonstrate that the PS1M146L mutant form, unlike wild type 
Presenilin 1, has no ability to activate p300 (Fig 4.1). In addition, virtually no 
enhancement in p300 activity was observed, in the absence of PS 1 transfection, 
when cells were treated with EcD, showing that EcD itself has no effect on p300 
activity (Fig 4.2). These experiments were routinely done with the addition of 
EcD to induce PS 1 expression. Moreover, no enhancement in p300 activity was 
observed, in the absence o f EcD, when the cells were transfected with wild type 
PS1 (Fig 4.2).
127
I  400-1
■  Gal-p300 full length
Control APS1 WT PS1
Figure 4.1 Effect o f with wild type or mutated PSlon the transcriptional 
activity o f p300 in FI 1 cells.
Luciferase assay results o f  co-transfecting F l l  cells with 2 pg o f the Gal4-E1B 
TATA-luciferase, 2 pg o f  the Gal-p300 (full length)-in the presence or absence o f 
with wild type or mutated PS 1(1 pg). Values are expressed relative to the level o f  
luciferase in control, neural cells transfected with Gal-luciferase and Gal-p300 
(set at 100%) and are the means o f  three independent transfection experiments 
whose standard error is indicated by the bars. * , p <  0.05 versus control.
128
ii
Gal-p300 full length
400-
300-
200-
100-
S
Figure 4.2 Effect o f Ecd and wild type PS1 on the transcriptional activity of 
p300 in F l l  cells.
Luciferase assay results o f  co-transfecting F l l  cells with 2 pg o f the Gal4-E1B 
TATA-luciferase, 2 pg o f  the Gal-p300 (full length)-in the presence or absence of 
with wild type PS1 (1 pg) -in the presence or absence o f  EcD (40 pM). Values are 
expressed relative to  the level o f  luciferase in control, neural cells transfected with 
Gal-luciferase and Gal-p300 (set at 100%) and are the means o f  three independent 
transfection experiments whose standard error is indicated by the bars. *, p < 0.05 
versus control.
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4.3 Regions of p300 involved in activation by WT PS1
In the previous chapter we demonstrated that PS1 activates different areas of CBP 
and it was shown that NGF can stimulate the transcription activating ability of 
independent regions p300(Liu et al., 1998). To determine whether a similar effect 
could be observed in the case of wild type PS land p300, we transfected a wide 
variety o f constructs containing different N-terminal and C-terminal regions of 
p300 linked to the Gal 4 DNA binding domain and analyzed their response to 
wild type PS land PS1M146L mutant form. In these experiments (Fig 4.3) no 
significant effect was observed with constructs containing the N-terminal region 
activation domain of p300 (amino acids 1-743, 242-1737, 964-1922 and 1514- 
1922). However, a decreased activity in response to wild type PS land its mutant 
was shown with the construct containing the region o f p300 from amino acids 
1737-2414 (Fig 4.3). In addition, decreased activity in response to wild type 
PS land a small non-statistically significant effect o f mutant PS1 was observed in 
the construct containing amino acids 1945- 2414.
130
lailiiiti
Control
WTPS1
APS1
Figure 4.3 Effect of wild type PSlon the transcriptional activity of different 
N-terminal and C-terminal regions of p300 in neural cell.
Luciferase assay results o f  co-transfecting F l l  cells with 2 pg o f the Gal4-E1B 
TATA-luciferase together with 2 pg o f  the p300 C-terminal regions (amino acids 
1514-1922, 1737-2414 or 1945-2414) or p300 N-terminal regions (amino 1-743, 
242-1737 or 964-1922) linked to Gal4 in the presence o f wild type PS 1(1 pg). In 
each case values are expressed relative to the level o f luciferase in untreated FI 1 
cells transfected with each construct (set at 100%) and are the means o f  three 
independent transfection experiments whose standard error is indicated by the 
bars. *, p < 0.05 versus the same construct without wild type Presenilin 1.
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4.4 Discussion
Similar to CBP, p300 has been shown to be a co-activator for a number of 
transcription factors (see section 1.6). Gene expression has been shown to play a 
role in the consolidation of long-term forms of synaptic plasticity and 
memory(Silva et al., 1998). In the case of FAD, initial study showed that PS1 
L286V mutant increased TCF/beta-catenin/CBP-mediated transcription. On the 
other hand, PS1 L286V mutant failed to activate TCF/beta-catenin/p300-mediated 
transcription, which lead to a decreas in neuronal differentiation (Teo et al., 
2005). However, regulation of p300 activity in response to wild type Presenilin 1 
and its M146L mutant has not previously been reported.
The data presented here add a new aspect to the mechanism by which the mutant 
of PS1 is involved in AD. Thus, wild type Presenilin 1, but not its M146L mutant 
form, was found to stimulate the transcriptional activation ability of p300. In 
addition, we showed that wild type Presenilin 1 and its M146L mutant form failed 
to increase the transcriptional activity o f the N-terminal domain of p300 and 
decreased the transcriptional activation ability o f the p300 C-terminal domain. 
This is surprising since the C-terminal domain of p300 had been shown to interact 
with the RNA polymerase holoenzyme complex as well as the transcriptional co­
activator p/CIP(Torchia et al., 1997). Moreover, p300 C-terminal region has been 
shown to be activated by phenylephrine and the p300 C-terminal homolog and 
region in CBP was demonstrated to be activated by WT PS1, showing that 
specific regions of CBP or p300 are involved in those effects. However, despite 
their high homology, the same signalling pathways were shown to target different 
regions of CBP and p300 to enhance their transcriptional activating ability
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(Gusterson et al., 2002). It is seems that the whole of p300 molecule is needed to 
get the activation effect of wt PS1.
The stimulation of the transcriptional activation ability of p300 by wild type 
Presenilin 1, but not by its M146L mutant form, supports a mechanism in which 
mutation of Presenilin 1 reduces p300 activity rather than enhancing it (Teo et al., 
2005). In addition, although that the precise domains of p300 which are activated 
as a response to wild type PS1 remain to be identified, it is already clear that the 
transcriptional activating ability of this critical co-activator is stimulated by wild 
type PS1 in neuronal cells. In addition, the M146L Presenilin 1 mutant shows 
partial loss o f function and may lead to reduced gene expression, which will cause 
memory loss and neurodegeneration in AD.
The original goal o f the work described in this chapter was to examine if the same 
general effects observed for CBP in chapter 3 also apply to p300. Moreover, we 
wanted to explore the possibility that p300 is involved in AD, since this was never 
shown before (Teo et al., 2005). So far, the results we obtained were very similar 
to those obtained for CBP. Therefore this work has not yet been extended further. 
It would be interesting in the future to perform confocal immunofluorescence 
experiments that would determine if wild type PS 1/PS 1 mutants have similar 
effects on p300 cellular localization, to those observed in the case of CBP. In 
addition, it would be o f value to test a wider range o f PS1 mutants for their effect 
on p300 transcriptional activity as shown in chapter 3 for CBP.
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Chapter 5
5 INVOLVMENT OF CBP HISTONE
ACETYLTRANSFERASE ACTIVITY IN ALZHEIMER’S 
DISEASE
5.1 Introduction
As mentioned in section 1.2.1, the acetylation of histones creates a more open 
chromatin structure, which makes the DNA more accessible to the transcriptional 
machinery and regulates the transcription of numerous genes. Furthermore, by 
acetylation of histones, CBP induces chromatin changes that results in the loss of 
transcriptional repression (see section 1.6). As shown in section 3.2 and by Saura 
et al. (Saura et al., 2004), CBP is involved in the development of AD. However, 
the mechanism of CBP involvement in the disease is unclear. The increased 
activity o f the CBP region containing amino acids 721-1679 induced by wild type 
PS1, which was demonstrated in section 3.5, was of particular interest since it 
contains the CBP acetyltransferase domain(Martinez-Balbas et al., 1998). We 
therefore decided to determine whether the histone acetyltransferase activity of 
CBP has any role in the stimulatory effect of WT-PS1. Here we will test a 
mechanism by which WT PS1 stimulates CBP to induce gene transcription and in 
particular relate it to its known HAT activity.
5.2 The effect of WT/mutant PS1 on c-fos luciferase expression
To further investigate the potential role CBP HAT domain in Alzheimer's disease, 
we wished to test the role of CBP in the activation of a natural promoter by WT 
PS1. To do this we used the promoter of the c-fos gene in a reporter luciferase 
construct. It has been shown that c-fos is one of the genes induced in the brain by
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CBP and is involved in memory formation and consolidation(Tischmeyer and 
Grimm, 1999). It has been demonstrated that the histone acetyltransferase activity 
o f CBP is required for normal c-fos promoter activation and that c-fos levels are 
significantly decreased in CBP [HAT-] mice(Korzus et al., 2004). As a result we 
decided to examine the effect of PS1 on the c-fos promoter.
The c-fos luciferase construct was therefore transfected into the FI 1/EcR line and 
the cells were either left untreated or transfected with wild-type or mutated 
Presenilin 1. EcD was used to induce Presenilin 1 expression, c-fos luciferase 
expression was activated by the wild type PS1 but not by its M146L mutant (Fig
5.1 A). In addition the activation of the c-fos promoter by WT PS1 was abolished 
by co-transfection o f a construct expressing full-length CBP in an antisense 
orientation (Fig 5.IB), indicating that CBP was involved in this effect. Hence, the 
role of CBP in the PS1 response can be demonstrated on a natural promoter by 
inhibiting endogenous CBP providing further evidence o f the importance of the 
HAT region in this activation. This shows that WT PS1 affects c-fos expression 
and it is CBP dependent. In addition, virtually no enhancement in c-fos luciferase 
expression was observed, in the absence of Presenilin 1 transfection, when cells 
were treated with EcD, showing that EcD itself has no effect on c-fos promoter 
activity (Fig 5.2A). These experiments were routinely done with the addition of 
EcD to induce Presenilin 1 expression. No enhancement in c-fos luciferase 
expression was observed, in the absence of EcD, when the cells were transfected 
with wild type Presenilin 1 (Fig 5.2A).
Moreover, evidence to show that CBP antisense eliminates CBP endogenous 
expression was provided using western blot analysis. Experiments were
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preformed in which F l l  cells were transfected with antisense CBP or an empty 
expression vector. The result of this experiment showed a dramatic decrease in 
levels o f endogenous CBP (fig 5.3), confirming that the cells transfected with 
antisense CBP show greatly reduced CBP expression.
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Figure 5.1 Effect of the wild type and mutant PS1 on c-fos luciferase 
expression.
A) Luciferase assay results o f  co-transfecting F l l  cells with 2 pg o f  the c-fos 
luciferase together with 1 pg o f wild-type 1 or mutant presenilin. Values are 
expressed relative to the level o f  luciferase in control (neural cells transfected with 
c-fos luciferase and 1 pg  o f  empty vector) set at 100%. Values are the means o f  3 
independent transfection experiments whose s.e. is indicated by the bars. * p<0.05 
vs control. B) Luciferase assay results o f  co-transfecting F l l  cells with 2 pg o f 
the c-fos luciferase together with 1 pg o f  wild-type 1 or mutant presenilin and 
with either 2.5 pg o f  empty expression vector or 2.5 pg o f  CBP antisense plasmid. 
Values are expressed relative to the level o f luciferase in control (neural cells 
transfected with c-fos luciferase and transfected empty vector) set at 100%. No 
significant difference was found.
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Figure 5.2 Effect o f EcD and W T PS1 on c-fos luciferase expression in F l l  
cells.
Luciferase assay results o f  co-transfecting F l l  cells with 2 pg o f  the c-fos 
luciferase -in the presence or absence o f  with wild type PS1 (1 pg) -in the 
presence or absence o f  EcD (40 pM). Values are expressed relative to the level o f 
luciferase in control, neural cells transfected with Gal-luciferase and Gal-CBP (set 
at 100%) and are the means o f  three independent transfection experiments whose 
standard error is indicated by the bars, p >0.05 versus control.
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Figure 5.3 Effect o f CBP antisense on endogenous CBP levels
Expression if  CBP in F l l  cells either w ith an empty vector (2.5 p.gr) or with 
different concentrations o f  CBP antisense construct. Values are means o f  three 
independent transfection experim ents whose standard error is indicated by the 
bars, p >0.05 versus control. Results were normalized against the control. *, p <
0.05 versus control
5.3 CBP, but not its HAT mutant, is stimulated by WT PS1
To further extend these studies, we utilized a construct in which full-length CBP 
contains a mutation (WY - amino acids 1503-1504 replaced by alanine and 
serine)(Bordoli et al., 2001b). This mutation, which completely abolishes the 
HAT activity of CBP, was linked to the DNA binding domain of Gal4. Either the 
full-length Gal-CBP HAT WT or WY constructs were transfected into the 
F ll/E cR  line together with the reporter luciferase construct, and the cells were 
either left untreated or transfected with wild-type or mutated PS1. As illustrated in 
Fig 5.3, the WY construct did not show enhanced promoter stimulatory activity in 
response to WT PS1, whereas this was observed as before with a construct 
containing full-length wild type CBP linked to Gal4. Both the HAT mutant or 
wild type CBP were not able to responded to the PS1 M146L mutant, as expected. 
In addition, there was no difference in the basal activity between WT and WY 
Gal-CBP (Fig 5.3). Thus, these findings suggest that a CBP mutant lacking HAT 
activity is not capable o f responding to WT-PS1 in terms of increased 
transcription activating ability.
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Figure 5.4 Relative luciferase Gal4 promoter activity of either W T-CBP or its 
mutant lacking H A T activity (W Y-CBP).
A) Luciferase assay results o f  co-transfecting FI 1 cells with 2 pg o f  the Gal4-E1B 
TATA -luciferase together w ith 2 pg o f  the luciferase gene and constructs 
containing either CBP W T or CBP W Y linked to the DNA binding domain o f  
Gal4 in the presence o f  w ild-type or mutant presenilin 1 (1 pg). Values are 
expressed relative to  the level o f  luciferase in control (neural cells transfected with 
G al-luciferase, Gal-CBP and 1 pg o f  em pty vector) set at 100%. Values are the 
means o f  3 independent transfection experiments whose s.e. is indicated by the 
bars. * p<0.05 vs control. B) Basal luciferase activity in FI 1 cells co-transfected 
with 2pg  o f  Gal4 D N A  binding sites upstream o f  the luciferase gene and 
constructs containing either CBP W T or CBP W Y linked to the DNA binding 
domain o f  Gal4. V alues are expressed as the light intensity. No significant 
difference w as found.
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5.4 Discussion
As discussed in section 1.6, CBP has been shown to possess HAT activity, and 
this activity has been shown to regulate gene expression including that of genes, 
which are important for long-term memory formation(Hallam and 
Bourtchouladze, 2006). As shown is chapters 3 and 4, the key role of CBP and 
p300 in AD is accompanied by an enhanced ability o f CBP and p300 to stimulate 
transcription following exposure o f F l l  cells to WT PS1. Here, we demonstrate 
that this effect is dependent on the HAT activity of CBP, because inactivation of 
such activity within a construct containing CBP linked to the Gal-4 DNA binding 
domain abolishes the enhanced activity normally observed in response to WT 
PS1.
To further extend these studies, we tested the role o f CBP in the activation of a 
natural promoter by WT PS1. To do this we used the promoter of the c-fos gene, 
which is involved in memory formation and is depended on CBP HAT 
activity(Tischmeyer and Grimm, 1999). We showed that c-fos luciferase 
expression was activated by the wild type WT PS 1. Remarkably, the Presenilin 1 
M146L mutant form produced virtually no enhancement in promoter activity. 
Moreover, the activation o f this promoter by WT PS1 was abolished by co­
transfection o f a construct expressing full-length CBP in an antisense orientation 
indicating that it was able to prevent a well characterized effect of CBP. Hence, 
the role o f CBP in the WT PS1 response can be demonstrated on a natural 
promoter by inhibiting endogenous CBP providing further evidence that it is not 
dependent on the use o f Gal4-CBP constructs.
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Furthermore, c-fos gene induction by CBP is depended by CBP HAT domain 
(Korzus et al., 2004). This suggests that the c-fos decreased in promoter activity 
in cells transfected with Presenilin 1 M146L mutant might be as a result of a 
decrease in CBP HAT activity. Therefore, the HAT activity of CBP appears to be 
essential for enhancing transcriptional activity ability in the presence of WT PS1.
The data presented here shows for the first time that CBP HAT region plays a key 
role in the response to WT PS1 stimulus and suggests that PS1 mutant form is not 
able to stimulate CBP HAT activity.
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Chapter 6
6 BENEFICIAL EFFECT OF HISTONE DEACETYLASES 
INHIBITOR TSA IN A MOUSE MODEL OF 
ALZHEIMER’S DISEASE
6.1 Introduction
The data presented in chapters 3 and 5 suggests that enhanced histone acetylation 
might reestablish normal gene transcription in AD. This histone acetylation 
enhancement could be achieved in three main ways:
1. Overexpression o f CBP
2. Specific enhancement of CBP HAT activity
3. Inhibition o f histone deacetylation
Although all o f the above approaches lead to histone acetylation enhancement, 
overexpression of CBP in an in vivo model involves some technical challenges. In 
addition, drugs for specific enhancement of CBP HAT activity are commercially 
unavailable. Therefore, it was decided to explore HDAC inhibitors to produce 
histone acetylation enhancement
As mentioned in section 1.2.1, HDACs remove an acetyl group from histones, 
thus restricting access of the transcriptional machinery to the DNA. HDAC 
inhibitors have been shown to enhance LTP and memory and learning in rats 
(Levenson et al., 2004). Moreover, in a transgenic mouse model of HD, 
administration of HDAC inhibitors improved brain morphology, survival, body 
weight and motor performance (Ferrante et al., 2003). Also, memory and LTP
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deficits of CBP+/_ mice were reversed by the administration of HDAC inhibitor, 
suberoylanilide hydroxamic acid (SAHA), supporting the potential use of this 
class o f drugs as therapeutic agents against mental retardation in RTS(Alarcon et 
al., 2004). Interestingly, HDAC inhibitors, such as SAHA and TSA, are currently 
being used in clinical trials for the treatment of some forms of cancer, based on 
their ability to suppress tumor cell proliferation by activating the transcription of 
genes involved in cell-cycle arrest, differentiation and/or apoptosis (Marks et al., 
2004). Given the role of the CBP HAT domain in AD and the positive effects of 
HDAC inhibitors in reducing neurodegeneration and improving survival and 
impaired behaviour in animal models of HD and RTS, this drug might also be 
effective in therapeutic approaches against AD (Fig 6.1).
However, F l l  cell line test conditions may not correspond to the conditions inside 
of the organism. Therefore, it was decided to extend our in vitro results with in 
vivo research. Diverse opportunities to examine the molecular basis of AD and 
intervene with the mechanisms causing the disorder are provided by transgenic 
mouse models overexpressing mutant forms of APP, PS1 and PS2(Wong et al., 
2002). One o f the most well-known models is the transgenic mouse expressing 
the familial Swedish mutation K670N:M671L in APP. This mouse shows 
increase o f brain Ap levels by 6-8 months of age followed by development of 
neuritic plaques in the neocortex and hippocampus(Frautschy et al., 1998; Hsiao 
et al., 1996; Irizarry et al., 1997) and impairment of the cognitive function by 9-10 
months(Chapman et al., 1999; Holcomb et al., 1998). Interestingly, the AD-like 
pathology is even more accentuated in mice obtained by crossing APP animals 
with the line 6.2 of PS1 (M146L) animals, which over express the FAD-linked
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PS1 M146L mutation. Consistent with studies in which a mutated APP gene is 
co-expressed with a mutated PS1 gene (Borchelt et al., 1997), the APP/PS1 (line 
6.2) mouse starts developing plaques at about 2 months(McGowan et al., 1999). 
Moreover, they have reduction in LTP by 3 months of age together with 
contextual fear memory impairment and spatial working memory. These findings 
suggest that AD-like dysfunctions might occur at earlier stages in double 
transgenic APP/PS1 mice compared with transgenic models with a single APP or 
PS1 mutation. Because o f the faster appearance of their phenotype, double 
transgenic mice are currently used by several laboratories for studies on the 
mechanisms of AD as well as for the development of a therapy to prevent and/or 
treat the disease. Consequently, it was decided to use an APP/PS1 AD mice model 
for our experiments.
Figure 6.1 HDAC inhibition.
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6.2 Effect of TSA on synaptic function in hippocampal slices of 
APP/PS1 mice
In the first series of experiments it was tested whether an inhibitor of histone de- 
acetylation can re-establish normal synaptic function in the APP/PS1 mouse. 
Synaptic dysfunction is thought to be one of the first alterations occurring in AD. 
Thus, a series o f experiments were performed to tested whether a brief application 
o f the HDAC inhibitor, TSA, was capable of rescuing the defect in LTP shown by 
brain hippocampal slices from 3 month-old APP/PS1 mice. At this age the 
APP/PS1 mice start showing synaptic plasticity impairment (Trinchese et al., 
2004). Hippocampal slices were perfused with TSA (1.65pM) for 30min before 
inducing late-phase LTP (L-LTP) through tetanic stimulation of the Schaeffer 
collateral pathway.
It was shown that potentiation in TSA treated APP/PS1 slices were far greater 
than in vehicle-treated APP/PS1 slices (Fig 6.2A). Two-way ANOVA revealed a 
significant difference between the two APP/PS1 groups and a WT comparisons 
showed that the groups were significantly different at each time point after the 
tetanus. On the other hand, TSA did not change the amplitude of LTP in 
hippocampal slices o f WT mice compared to WT slices treated with vehicle alone 
(Fig. 6.2B). Moreover, TSA had no effect in the basal synaptic responses in slices 
from APP/PS1 mice or WT littermates either during TSA application or 120 min 
after the end o f the application in experiments in which no tetanic stimulation was 
applied (n=3; Fig 6.2). Thus, this shows that inhibitors of histone de-acetylation 
are able to re-establish normal synaptic function in the APP/PS1 mouse.
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Figure 6.2 TSA reverses CA1-LTP impairment in slices from APP/PS1 mice.
(A) Summary o f  the graph showing that 30 min o f HD AC treatment abrogates 
LTP impairment in APP/PS1 mice without affecting the baseline transmission 
(n=5, P<0.005). (B) Summary graph showing that 30min o f  treatment with TSA 
does not effect LTP and baseline transmission in WT mice (n=5, P>0.05). These 
experiments were interleaved with those o f  WT mice. The horizontal bar 
represents TSA application. The 3 arrows correspond to the theta-burst.
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6.3 Effect of TSA on the cognitive function of APP/PS1 mice
Since the electrophysiological studies showed that TSA ameliorated LTP deficits 
in 3-month-old double-transgenic mice, Itwas then tested whether TSA was 
capable of reversing behavioural impairment in these animals. Our initial studies 
examined the effects o f acute administration of TSA on hippocampus-dependent 
memory. Fear-conditioning learning was used as a test of hippocampus-dependent 
memory. This test involves different forms of explicit learning and has been found 
to be impaired at the age o f 3 months in the double-transgenic mice(Trinchese et 
al., 2004). The hippocampus, in particular, is indispensable for contextual fear 
conditioning(Phillips and LeDoux, 1992), a form of associative learning in which 
mice must associate a neutral stimulus with an aversive one. This type of 
cognitive test is more rapid than other behavioural tasks that require multiple days 
of training and testing.
In a series o f preliminary experiments, it was tested whether the APP/PS1 and WT 
mice had different perceptions of an electric shock. Notably, the shock threshold 
is the same for mice o f the different genotypes(Gong et al., 2004). APP/PS1 and 
WT littermates 3 months of age were subjected to a standard fear-conditioning 
paradigm(Bourtchuladze et al., 1994). 2 hours after injection of TSA (2 pgr/gr 
body weight; i.p), the animals were placed in a novel context (fear-conditioning 
box) and were exposed to a mild foot shock (training phase of the fear 
conditioning). Conditioning was assessed 24 hours later by measurement of 
"freezing" behaviour —  the absence of all movement except for that necessitated 
by breathing —  in response to the context (contextual conditioning).
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During the training phase, no difference in the freezing of APP/PS1 mice treated 
with TSA or with vehicle compared with that of TSA- or vehicle-treated WT 
littermates was found (Fig 6.3A). Two-way ANOVA followed by the Bonferroni 
test revealed no significant difference between the 4 groups (Fig 6.3A) [P > 0.05].
Twenty-four hours later we found a decrease in the freezing time of vehicle- 
treated APP/PS1 mice compared with that of vehicle-treated WT littermates in 
contextual conditioning was demonstrated (vehicle-treated APP/PS1 mice 
demonstrated about 46% that of vehicle-treated WT mice; 14.88 ± 3.22% in 
APP/PS1, n = 13, 8 females plus 2 males, versus 31.68 ± 5.31% in WT 
littermates, n = 13, 8 females plus 2 males; Fig 6.3B). However, the freezing time 
was increased in APP/PS1 mice after the injection of TSA (TSA-treated APP/PS1 
mice demonstrated about 110% that of vehicle-treated WT mice: 35.04 ± 6.43%, n 
= 13, 8 females plus 2 males; Figure 6.3B).
The freezing responses o f TSA-treated APP/PS 1 mice were similar to those of 
vehicle-treated WT littermates. WT animals treated with TSA showed a 
nonsignificant increase in freezing (about 116% that of vehicle-treated WT mice: 
36.95 ± 6.42%, n = 13, 8 females plus 2 males), probably because maximal levels 
of memory are already induced in vehicle-treated WT mice after the training 
session, as has been found both in Drosophila and in mice(Tully et al., 2003).
Two-way ANOVA followed by the Bonferroni test revealed a statistically 
significant difference between the 4 groups (P < 0.01). Post-hoc analysis showed a 
statistically significant difference between vehicle-treated APP/PS 1 and vehicle-
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treated WT littermates (P < 0.05) as well as between TSA-treated and vehicle- 
treated APP/PS1 mice (P < 0.01). Thus, this shows that inhibitors of histone de- 
acetylation are able to re-establish normal memory in the APP/PS 1 mouse.
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Figure 6.3 TSA injections improve contextual conditioning performance in 3- 
month-old APP/PS1 mice.
(A) Three-month-old APP/PS 1 and WT littermates treated with TSA or vehicle 30 
minutes prior to testing show no difference in immediate freezing in the training 
chamber (P > 0.05). (B) Three-month-old vehicle-treated APP/PS 1 mice show 
reduced freezing responses compared with vehicle-treated WT littermates during 
contextual fear conditioning performed 24 hours after training. Injection o f  TSA 
the day before ameliorates the deficit in freezing responses in APP/PS1 mice. 
TSA has no effect on the freezing responses in WT mice (P < 0.01).
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6.4 Effect of TSA on histone acetylation in APP/PS1 mice
As discussed in section 1.2.1, histone acetylation changes the net charge of 
nucleosomes, resulting in the relaxation of DNA-histone interactions, altering the 
chromatin structure that enables gene transcription. It was previously that CBP 
and its HAT activity appear to be essential for enhancing transcription in vitro 
following PS1 stimulation (see chapters 3 and 5). Moreover, acetylation o f histone 
H3 on Lys-14, a residue that has been implicated in transcription regulation 
(Angus-Hill et al., 1999; Cheung et al., 2000), is increased 1 hr after training for 
fear conditioning(Alarcon et al., 2004; Levenson et al., 2004). Therefore, it was 
decided to test if the deficits observed in APP/PS 1 mice arise as a consequence of 
altered chromatin structure due to the reduced activity o f CBP.
To address these questions, it was decided to measure acetylation of histones H4 
in hippocampus from WT and APP/PS 1 animals. Vehicle control solution was 
administered i.p. 2 hours before fear conditioning training. 1 hour after contextual 
fear conditioning, the APP/PS 1 and WT mice were euthanized and hippocampus 
was extracted. Western blot analysis of hippocampal extracts demonstrated that 
compare to WT miceAPP/PSl mice showed an overall reduction of more than 
50% in acetylated histone 4 levels (Figures 6.4). It was next asked whether HDAC 
inhibition might rescue the histone 4 acetylation levels defect observed in 
APP/PS 1 mice. It was found that injection of TSA (2 pgr/gr body weight; i.p) 2 
hours prior to contextual fear conditioning enhanced H4 acetylation of APP/PS 1 
mice (Fig 6.4). This demonstrates that AD is disease with an epigenetic motifes 
and that HDAC inhibitors are able to elevate the decreased levels of histone 4 in 
AD mouse.
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Figure 6.4 Rescue of histone H4 acetylation by TSA in 3-4 month old 
APP/PS 1 mice.
Western blot using acetylated H4 antibody o f  protein extract from mice that were 
euthanized 1 hour after contextual fear conditioning. APP/PS 1 and WT mice were 
treated with vehicle or TSA, 2 hours before training. This experiment was 
repeated three timed with similar results. Results were normalized against WT 
vehicle. *, p < 0.05 versus control.
6.5 Discussion
The use of HDAC inhibitors in rodents has demonstrated the role of chromatin 
modification for transcriptional regulation underlying memory processes(Alarcon 
et al., 2004; Korzus et al., 2004; Levenson et al., 2004; Oike et al., 1999b; Vecsey 
et al., 2007). However, this is the first study to identify AD as a disease of 
epigenetic etiology. Our findings on the AD model indicate that the cognitive 
deficits observed in APP/PS 1 mice mutants may be a consequence of a reduced 
HAT activity. Our results suggest that CBP HAT activity might be involved in 
AD impairments. Here we have showed that HDAC inhibition enabled the 
recovery o f impaired learning after AD mice had developed severe 
neurodegeneration and synaptic function loss. Our results suggest that the effect 
of HDAC inhibition is likely to be mediated, at least in part, by re-elevation in 
acetylation o f histones H4, which might initiate synaptic growth. These results 
correlate with our previous in vitro observations, which show that CBP 
stimulation by WT PS 1 is dependent on CBP HAT domain.
It is important to note that the effect of HDAC inhibitors on learning and memory 
could be a combination o f modifications on chromatin and non-histone proteins, 
because it has been reported that some HDACs also target non-histone 
substrates(Yuan et al., 2005). Moreover, it is possible that different classes of 
HDACs are distinctly involved in synaptic plasticity. For example, it has been 
shown that HDAC5 is associated with downregulation o f certain brain-derived 
neurotrophic factor (BDNF) transcripts in a social defeat paradigm, a 
phenomenon that can be reversed with HDAC inhibitor treatment(Tsankova et al.,
2006).
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It is unclear from these results if CBP or other HATs deregulations are the cause 
for H4 decreased of acetylation. However, it has been shown that the 
enhancement of hippocampus-dependent memory and hippocampal synaptic 
plasticity by HDAC inhibitors is mediated by the activation of key genes 
regulated by the CREB:CBP transcriptional complex(Vecsey et al., 2007). This 
suggests that HDAC inhibitors could be used to treat cognitive disorders that are 
associated with deregulated CBP activity or decreased CBP levels.
Interestingly, ‘rewiring’ o f the brain and recovery of memory, using HDAC 
inhibitors, was recently reported in a neurodegenerative mice model(Fischer et al.,
2007). Therefore, it is possible that HDAC inhibitors would be capable of re­
establishing neural networks in AD brain model. If so, this suggests that using 
small molecules that target HDACs in AD patients could facilitate access to long­
term memories.
The therapies for AD that are currently in use include augmentation of the 
cholinergic system by inhibition of acetylcholinesterases or, more recently, the 
use of NMDA antagonists that may act by blocking glutamate neurotoxicity. 
These agents have a limited efficacy and only the latter appears to have an even 
modest effect on the course o f the disease. A major effort is underway to decrease 
the Ap load in the brain either by the use o f agents that block the secretases that 
process APP to A(3 or by the use of treatments, such as immunization with Ap, 
that appear to augment the removal of Ap from the brain(Schenk et al., 1999). 
Animal studies have demonstrated that the neuritic dystrophy that develops in 
animals that overproduce Ap can be reversed by immunization (by Ap antibodies)
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that removes Ap from the brain(Lombardo et al., 2003). Unfortunately, human 
trials of an Ap vaccine had to be terminated because of encephalitic complications 
in some o f the patients(Nicoll et al., 2003). TSA and other HDAC inhibitors 
represent a new approach to treatment that appears to make the synapse more 
robust and resistant to the effects o f Ap. Our results suggest not only that TSA is 
capable o f stopping memory degradation in the presence of Ap accumulation but 
also that it may improve function in a brain that, as in the case of the 3-month-old 
double-transgenic mouse, has already lost function. Novel HDAC inhibitors in 
which the side effects have been minimized are being developed by the 
pharmaceutical industry. It remains to be seen if these newer inhibitors can readily 
enter the brain and if they are as effective as TSA.
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Chapter 7
7 DISCUSSION
The work presented in this thesis is an investigation into the effect of WT PS1 and 
its mutant form on the transcriptional activity of CBP and p300 in AD, and of a 
possible therapeutic method for treating AD symptoms. In addition, the signalling 
pathways involved in the stimulus effect of CBP and p300 by WT PS1, but not by 
its mutant, were studied. Moreover, the specific regions of CBP activated by WT 
PS1 were localised, thus providing a further understanding of the molecular 
mechanism involved in the stimulation effect of WT PS1 stimulus effect. 
Additionally, the HAT activity of CBP was studied and an HDAC inhibitor was 
used in AD mice model in order to provide a better understanding of CBP role in 
AD.
Although in previous investigations CBP has been linked to AD, the role of PS1- 
CBP interaction in neurodegeneration, as is shown in the literature, is unclear and 
inconsistent. Moreover, no studies have directly tested CBP and p300 
involvement in the disease. In addition, CBP/p300 have been shown to be 
associated with the human developmental disorder Rubinstein-Taybi syndrome, 
which is characterised by mental retardation. In view of this, we began to 
investigate the potential role of CBP in AD by studying its activity and the effects 
of manipulating its expression in cells containing wild type or mutant forms of 
PS1, which is mutated in the FAD.
The initial results presented in chapter 3 show that WT PS1 stimulates CBP 
activity over 2 fold. Therefore, an increase in CBP activity might be expected 
when stimulated with the presenilin 1 M146L mutant, however, no such increase
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in activity was seen suggesting that the presenilin 1 M146L mutant cannot 
stimulate CBP activity directly. Moreover, the transfected Gal-CBP levels were 
shown not to change, suggesting the changes of CBP activity is as a result of 
changes in CBP enzymatic activity.
However, overall CBP activity could, in addition to changes in its enzymatic 
activity, also be altered by changes in its expression. We therefore measured 
endogenous levels o f CBP and were able to show an increase in endogenous CBP 
when WT PS1 or its PS1-M146L mutant were transfected. However, CBP 
endogenous levels, when PS1-M146L was transfected, were significantly lower 
compared to the endogenous levels of CBP when WT PS1 was transfected. This 
suggests that, in addition to a decrease in CBP protein activity, decreased CBP 
levels might also be involved in the development of AD.
It is important to note that while wild type PS1 increases endogenous CBP level 
more than PS1- M146L mutant, this does not account for our Ga4-CBP results. 
Gal4-CBP activity changes cannot be explained by changes in Gal4-CBP level 
since Gal4-CBP. levels stay the same during the luciferase experiments. 
Consequently effects on Gal4 promoter must be due to changes in CBP activity, 
enhancing its ability to activate transcription.
All the experiments discussed thus far use Gal4-CBP fusion proteins, which have 
in the past been criticised(Cardinaux et al., 2000). It has been suggested that the 
transcriptional activation function seen in Gal4-CBP is masked in the 
conformation o f naive CBP. Moreover, this conformation might not be
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recapitulated precisely in the molecule that is targeted to a promoter through a 
heterologous DNA binding domain at its amino terminus. To overcome this 
observation, immunofluorescence of CBP was used to show the different effect of 
wild type and mutated PS1 on its cellular localization. The effect of WT and 
mutant PS1 on CBP localization were consistent with previous results showing 
stimulation of transcription by WT PS1, but not by its mutant form, thus 
confirming their validity.
As discussed in section 1.8.6, it was shown that PS1 may be involved in the 
processing and trafficking of membrane-bound proteins including the Notch 
receptor (Levitan and Greenwald, 1995; Wong et al., 1997), whereas PS1 protein 
deficiency and PS1 mutations block the endoproteolytic cleavage of Notch. In 
turn, Notch intracellular cytoplasmic domain (NICD), which is released from the 
Notch after endoproteolysis, translocates to the nucleus, where it is needed for 
modifying transcription of specific genes such as CBF1 (also known as RBP-Jk). 
Interestingly, Saura el al (2004) found that the predicted CBP promoter contains a 
consensus recognition site for the transcription factor CBF1 through which the 
active form of the Notch intracellular domain exerts its transcriptional activation 
effects. This suggests that CBP is likely a downstream target gene of the Notch 
signalling pathway (Saura et al., 2004). This might explain how F ll  cells 
expressing WT PS1 showed significantly higher levels of CBP than in F ll  cells 
expressing PS1-M146L mutant or knockdown of PS1 (Fig 7.1).
An additional explanation to the increase in endogenous CBP levels, when WT 
PS1 is transfected, is that CBP localisation to the nucleus might protect CBP from
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degradation. It would be intresting to see if CBP levels are regulated at the mRNA 
and/or protein level. We could use transcription inhibitors and test if CBP levels 
change with transfection o f WT/mutant PS1. At the same time we could measure 
CBP total/nucleus levels to see if there are any changes.
Additionally, we were able to show generality with regards to the effect PS1 
mutants have on CBP transcriptional activity. We were able to show that both N 
and C-terminal mutations of PS1 were not able to stimulate the transcriptional 
activation ability of CBP. Moreover, PS1 C-terminus mutations showed a 
decrease in CBP activity compared to control vector or PS1 N-terminus 
mutations. It is possible that the C- terminus mutants bind to a cellular protein, 
which regulates CBP activity, and inhibit this protein from being activated by 
endogenous PS1. In contrast, it is possible that N-terminus mutants do not bind to 
the cellular protein, which regulates CBP activity, and therefore do not inhibit its 
activation by endogenous PS1. N-terminus mutants therefore have no effect on 
CBP activity. It would be interesting to see if transfection of wild type PS1 would 
be able to produce a positive effect in the presence of N-terminal mutants, but not 
of the C-terminal mutants, as would be predicted by this model.
Since the activity of CBP was measured indirectly using constructs in which CBP 
was fused to the GAL-DBD, experiments were preformed to look at the effect of 
WT PS1 on the GAL-DBD portion of the protein alone to confirm that the results 
seen were valid. Indeed co-transfection of the GAL-DBD and a reporter construct 
showed no increase in reporter gene activity when cells were transfected with WT
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PS1. This indicated that the transcriptional activity observed with Gal-CBP 
protein was due to the CBP portion of the construct.
Details of the pathway involved in the CBP up-regulation by WT PS1 came from 
experiments showing that inhibition of the PI 3-kinase, p38 MAP kinase and 
p42/p44 MAP kinase pathways, with the chemical inhibitors LY 294002, SB 
203580 and PD 98059 respectively, blocked the increased activity of CBP 
induced by WT PS1. Theses results suggest that the up-regulation of CBP activity 
by WT PS1 was via these kinases pathways. Notably, chemical inhibitors are not 
generally very specific. Although they predominantly inhibit one kinase, they can 
inhibit other kinases. This lack of selectivity could be a problem and that it is 
worth following up these inhibitors, by transfecting dominant negative constructs 
of particular kinases, so as to get a more specific inhibitory effect.
It has been shown that three different main GluRs: AMPA, kainate and NMDA 
receptors activation are important for learning and memory (Bliss and 
Collingridge, 1993). The activation of these receptors leads to an activation of 
kinases, such as PKA, PKC, CaMKIV and MAPK. In addition to regulating 
CREB phosphorylation, all of these kinases have been shown to increase CBP 
activity. Interestingly, NMDA and MAPK activity has been shown to be reduced 
in activity in rodent with PS1 mutation (Ma et al., 2007; Wang et al., 2007). This 
might lead to a reduction in CBP activity and gene transcription, which are 
important for memory condensation (Fig 7.2).
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Using small CBP fragments linked to Gal4 it was shown that activity of the CBP 
C-terminal region (amino acids 2173-2288) or CBP N-terminal regions (amino 
acids 1^160, 721-1679, 1678-1843) was increased over 2 and 1.5 fold 
respectively by WT PS1. However, the presenilin 1 M146L mutant form produced 
virtually no enhancement in stimulating activity of these regions, showing similar 
activity levels to the untreated cells. These results demonstrate that the presenilin 
1 M146L mutant form, unlike wild-type Presenilin 1, has no ability to activate 
different regions of CBP. Notably, the decreased activity of the CBP region 
containing amino acids 721-1679 induced by presenilin 1 M146L mutant form 
was of particular interest since it contains the CBP acetyltransferase domain 
(Martinez-Balbas et al., 1998).
Since CBP and p300 are highly homologous proteins and are structurally similar, 
some of the experiments preformed for CBP were also done for p300. As in the 
case of CBP, p300 was shown to have enhanced activity when stimulated by WT 
PS1, but not by its mutant form. Interestingly, wild type Presenilin 1 and its 
M146L mutant form failed to increase the transcriptional activity of different 
regions of p300. This shows that the same stimulation can activate different 
regions of similar proteins. Also, multiple regions of the proteins may be involved 
both in the case of CBP and p300. In the case of CBP we demonstrated an effect 
when each of CBP regions is tested independently, whereas with p300 we might 
need to have all o f p300 regions in the same construct to get a stimuli effect. It 
would be of interest to follow up the effect of WT PS1 on different regions of 
p300 by using point mutation in different regions.
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The results thus far indicated a potential role for CBP and p300 in AD by 
responding to WT PS1 stimulation, but not to its FAD mutant. By using an 
antisense CBP construct, this hypothesis could be tested more directly. Use of the 
c-fos luciferase system confirmed this hypothesis by showing that the activation 
of the c-fos CRE promoter by WT PS1 is inhibited in cells co-transfected with 
antisense CBP.
CBP possesses HAT activity, which has previously been shown to increase their 
transcriptional activity(Martinez-Balbas et al., 1998). To identify the structural 
features of CBP involved in the stimuli response to WT PS1, a HAT mutation was 
used. The increased activity of the Gal4-CBP WT reporter gene induced by WT 
PS1 was not seen in cells transfected with the CBP HAT mutant construct. This 
demonstrates that WT PS1 stimuli effect is dependent on the HAT activity of CBP 
and it adds a new aspect to the mechanism by which the mutant of PS1 might be 
involved in AD. The HAT domain lies in the region 1200-1600 amino acids, 
inside the C-terminus which has been shown to increase promotor activity when 
stimulated by WT PS1. From these results, and work preformed by others(Ait-Si- 
Ali et al., 1999), it can be predicted that in the CBP full length protein, 
phosphorylation at the C-terminus will induce a conformational change of the 
CBP molecule that will allow the HAT domain to be more active.
The results so far suggest that it is the HAT activity of CBP, which is responding 
to the stimulating effect of WT PS1, but not to it PS1 mutant form. To further 
investigate this theory, an inhibitor of histone deacetylase activity, trichostatin A 
(TSA), was used to look at the effect of increased histone acetylation in an AD
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mouse model. As predicted TSA was able to re-establish normal synaptic function 
in the APP/PS 1 mouse by increasing potentiation in TSA treated APP/PS 1 slices, 
which was far greater than in vehicle-treated APP/PS 1 slices. Moreover, TSA was 
able to rescue normal memory in the APP/PS 1 mouse as demonstrated by the 
improved contextual learning of APP/PS 1 mouse treated with TSA.
To investigate the molecular mechanisms of TSA rescue, hippocampal neurons 
from APP/PS 1 and WT mice were tested for their level of histone acetylation. As 
predicted, APP/PS 1 mice displayed a decrease in histone 4 acetylation levels 
compared to WT mice, suggesting that AD might be a disease of epigenetic 
etiology. Remarkably, TSA administration to APP/PS 1 and WT mice was able to 
rescue APP/PS 1 mice reduced acetylation. This suggests that the rescuing of LTP 
and memory in APP/PS 1 mice by HDAC inhibition is likely to be mediated, at 
least in part, by re-elevation in acetylation of histones H4.
Beneficial effects of histone acetylation in memory-related plasticity had 
previously been described both in WT animals and in animal models of human 
mental retardation(Alarcon et al., 2004; Korzus et al., 2004; Levenson et al.,
2004). The importance of the work described in this thesis is that it shows, for the 
first time, that promoting histone acetylation restores learning, after synaptic and 
neuronal loss had already occurred. Together, these findings provide compelling 
evidence that increased histone acetylation can overcome the decrease of memory 
function seen in this AD mouse model.
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The stimulation of the transcriptional activation ability of CBP by WT PS1, but 
not by its mutant form, does not correlate with recent studies reporting that the 
mutation in PS1 would caused enhanced levels of CBP which will promote 
neurodegeneration(Marambaud et al., 2003; Teo et al., 2005). However, our work 
correlates with a previous study which showed reductions in CBP levels and in 
CRE-dependent gene expression in the PS 1 and 2 conditional double knockout 
mice(Saura et al., 2004) hence suggesting that decreased synthesis/activity of CBP 
may be important in the neurodegeneration observed in AD. Moreover, CBP- 
dependent gene expression has been demonstrated to play an important role in the 
consolidation of long-term forms of synaptic plasticity and memory. In our study 
we found a consistent reduction in CBP/p300 activity, including a specific 
reduction in CBP HAT activity that might have caused a reduction in histone 4 
acetylation. Since CBP is an essential cofactor for the formation of long-term 
memory, diminished CBP activity represents the likely basis for the global 
reduction of memory consolidation in APP/PS 1 mutant mice. While the basis for 
the discrepancy between the two studies is unclear, it may reflect differences in 
methodology or experimental system (i.e., cell culture versus adult brain).
The above data suggests that CBP and its HAT activity are essential for enhancing 
transcription in vitro following WT PS1 stimulation. It would be interesting to 
perform further experiments that will to determine CBP levels and HAT activity 
in mouse model of AD. In addition, it would be of value to test for acetylation 
levels in other histone than histone 4. Moreover, it is possible that the reduction in 
histone 4 acetylation rises from an increase in HDAC activity and not a reduction 
of HAT activity. Thus, it would be important to determine HDAC activity in
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App/PS 1 mice and compare it to WT mice. Furthermore, it is important determine 
whether HDAC inhibitors, other than TSA, will be able to re-establish synaptic 
function and normal memory in the APP/PS 1 mouse.
Recent studies indicate that there are alterations in immune cell function in AD, 
and a role for PS1 in immune regulation has been suggested recently. Thus, PS1- 
mutant M l46V knockin mice have been shown to have defects in its immune 
function(Morgan et al., 2007). Therefore, it would be of interest to see if a similar 
decrease in histone acetylation can be found in T lymphocytes. Lastly, it would be 
worth testing if the same histone acetylation difference appears in human brains of 
Alzheimer’s patients, which represents a more accurate model for the disease.
The work reported in this thesis leads to many interesting areas of research for 
future work, and is the first direct evidence for the involvement of CBP and p300 
in AD. It introduces the possibility of novel therapies targeting CBP and p300 and 
in particular histone acetylation, it also adds some understanding to the conflicting 
literature obtained to date as to how CBP and p300 are involved in AD.
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Figure 7.1 Notch-PSl pathway
Ligand-receptor interactions lead to y-secretase cleavage o f Notch and release o f 
the intracellular domain (NICD). This domain enters the nucleus and together 
with a complex including CBF1 and MAML promotes the transcription o f targets 
such as the Hes, Herp and CBP genes (figure adapted from (Yoon and Gaiano,
2005)).
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Figure 7.2 Signal transduction mechanism for long-term memory and its 
potential deregulation by PS1 mutant form.
A variety o f  signal pathways contribute to creation and reinforcement o f memory 
in the hippocampal neurons, which lead to protein synthesis. Mutated forms o f 
presenilin that are associated with Alzheimer’s disease are thought to accelerate 
the production o f  toxic amyloid plaques. These presenilin mutants also interrupt 
NMDA and MAPK activation. This might lead to a decrease o f  CBP activation, 
which is downstream from NMDA and MAPK. Therefore, as well as provoking 
amyloid-related neurotoxicity, presenilin mutations might cause Alzheimer’s 
disease by inappropriately deactivating genes associated with neuronal function 
and memory formation (figure adapted from (Voglis and Tavernarakis, 2006)).
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